

BMJ Open

What types of frailty predict death in HIV-infected women? The Women's Interagency HIV Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013993
Article Type:	Research
Date Submitted by the Author:	23-Aug-2016
Complete List of Authors:	Gustafson, Deborah R.; Suny Downstate Med Ctr, Neurology Shu, Qiuhu; New York Medical College School of Health Sciences and Practice, Epidemiology and Community Health Holman, Susan; SUNY Downstate Medical Center College of Medicine, Medicine Minkoff, Howard; Maimonides Medical Center, Cohen, Mardge; Rush University, Medicine Plankey, PhD, Michael; Georgetown University, Infectious Disease Epidemiology Havlik, MD, MPH, Richard; Arrow Health, Internal Medicine Sharma, Anjali; Yeshiva University Albert Einstein College of Medicine, Epidemiology Infectious Disease Gange, Stephen ; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Gandhi, Monica; University of California San Francisco School of Medicine, Infectious Disease Milam, Joel; Keck School of Medicine of the University of Southern California, Preventive Medicine Hoover, Donald; The State University of New Jersey, Department of Statistics
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Epidemiology, Infectious diseases, Neurology, Geriatric medicine
Keywords:	Frailty, HIV, HCV, Aging

SCHOLARONE™
Manuscripts

What types of frailty predict death in HIV-infected women? The Women's Interagency

HIV Study

Deborah R. Gustafson, MS, PhD^a; Qiuhi Shi, PhD^b; Susan A. Holman, RN, MS^c; Howard Minkoff, MD^{d,e}; Mardge H. Cohen, MD^f; Michael W. Plankey, PhD^g; Richard Havlik, MD, MPH^h; Anjali Sharma, MD, MSⁱ; Stephen Gange, PhD^j; Monica Gandhi, MD^k; Joel Milam PhD^l; Donald R. Hoover MPH, PhD^m

^aDepartment of Neurology, State University of New York - Downstate Medical Center, Brooklyn, NY; ^bSchool of Health Sciences and Practice, New York Medical College, Valhalla, NY; ^cDepartment of Medicine, State University of New York - Downstate Medical Center; ^dMaimonides Medical Center, Brooklyn, NY; ^eDepartment of Obstetrics and Gynecology, State University of New York - Downstate Medical Center, Brooklyn, NY; ^fDepartments of Medicine, Stroger Hospital of Cook County Health and Hospital System and Rush University; ^gDepartment of Medicine, Division of Infectious Diseases, Georgetown University Medical Center; ^hAIDS Community Research in American, New York, NY; ⁱDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY; ^jDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; ^kDepartment of Medicine, University of California, San Francisco (UCSF); ^lDepartment of Preventive Medicine, University of Southern California; ^mStatistics and Biostatistics & Institute for Health, Health Care Policy and Aging Research Rutgers the State University of New Jersey.

Deborah R. Gustafson, PhD, MS (corresponding author)

1
2
3 Professor, Department of Neurology
4

5 SUNY Downstate Medical Center
6

7 450 Clarkson Ave, MSC 1213
8

9
10 Brooklyn, NY 11203
11

12 deborah.gustafson@downstate.edu
13

14 718-270-1581
15
16
17
18

19 Running head: Frailty in HIV+/HIV- women
20

21 **Key Words:** Frailty, HIV, HCV, Aging
22
23
24
25

26 DISCLOSURE STATEMENT: The authors have nothing to disclose.
27

28 Abstract Word Count: 214/250 allowed
29

30 Text Word Count: 2840
31

32
33 1 Figure, 4 tables
34

35 References: 32
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives. Predicting mortality in middle-aged HIV-infected (HIV+) women on antiretroviral therapies (ART) is important for understanding the impact of HIV infection. Several indices have been used to predict mortality in women with HIV infection. We evaluated: 1) a modified HIV biological index, Veterans Aging Cohort Study (mVACS); 2) physical index, Fried Frailty Index (FFI); and 3) modified mental health index, Centers for Epidemiologic Studies-Depression (mCES-D). Proportional hazards regression analyses was used to predict death and included relevant covariates.

Design. Prospective, observational cohort

Setting. Multicenter, across 6 sites in the United States

Participants. 1385 multirace/ethnic HIV+ women on ART in 2005

Primary and secondary outcomes. All deaths, AIDS-deaths and non-AIDS deaths up to ~8 years from baseline

Results. Included together in one model, mVACS Index was the dominant, significant independent predictor of all deaths within 3 years (HR=2.21, 95% CI 1.84, 2.65, $\chi^2=72.5$, $p<0.0001$), and later than 3 years (HR=1.59, 95% CI 1.33, 1.89 $X^2=26.8$, $p<0.0001$); followed by FFI within 3 years (HR=2.11, 95% CI 1.23, 3.59, $\chi^2=7.46$, $p<0.0063$) and later than 3 years (HR=2.44, 95% CI 1.59, 3.73, $X^2=16.9$, $p<0.0001$). CES-D score was not associated with mortality.

Conclusions and Relevance. This is the first simultaneous evaluation of three common mortality indices in HIV infected adults. Indices reflecting physical and biological aging were associated with death.

Article summary

Strengths and limitations of this study

- Longitudinal cohort study with follow-up of almost 10 years
- Well-phenotyped White, African American and Latina HIV+ women
- Reputable standardized and validated physical, biological and emotional frailty indices

For peer review only

INTRODUCTION

HIV infection continues as a major global health issue affecting approximately 36 million people worldwide. HIV infection has evolved from a fatal infection to a treatable, chronic condition of aging,^{1,2} accompanied by multiple morbidities and rising healthcare costs. The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), observed that life expectancy of HIV infected adults increased from 36 to 51 years between 2000 and 2007,³ primarily due to treatment advances. In 2015, over half of HIV-infected Americans are ≥ 50 years old.³ Therefore HIV infection may prove to represent a modern-day phenomenon of achieving healthy old age accompanied by improved longevity.

Predicting death in chronic HIV infection may assist in the design of interventions to understand, prevent, cure or minimize age-related impairments, improve health and increase lifespan. Several indices predict death in adults with HIV infection - the Veterans Aging Cohort Study (VACS) Index; Fried Frailty Index (FFI); and the Centers for Epidemiologic Studies – Depression (CES-D) score. Each index can be considered an index of frailty, since each worsens with age and denotes weakness. The only HIV-specific mortality index is the VACS Index, which has been reproduced in North American and European patient populations including Highly Active ART (HAART) users in the Women’s Interagency HIV Study (WIHS).^{4,5} The VACS Index creates a clinical HIV mortality risk score by summing pre-assigned points for age, routinely monitored indicators of HIV disease and general indicators of organ system function.^{5,6} The Fried Frailty Index (FFI) is most commonly used when describing aging in both general and HIV-infected populations.^{7,8} Frailty is a common co-morbidity of HIV infection, observed even during middle age.^{4,9} The FFI includes measures of gait speed, handgrip strength, body weight loss, physical activity, and exhaustion and predicts death.¹⁰⁻¹² The Centers for Epidemiologic Studies –

1
2
3 Depression (CES-D) score measures mental health¹³ and has been independently associated with
4 mortality, particularly among women with HIV infection on HAART in the WIHS.⁴
5
6
7
8
9

10 The objective of our analyses was to evaluate, among HIV-infected women, the association of
11 the aforementioned indices: VACS, FFI, and CES-D, with death (both AIDS-and non-AIDS
12 related). All indices were measured in mid-life (average age 39 years) in our analyses and
13 evaluated for prediction of mortality for up to ~8 years. This follow-up period was further broken
14 down into short-term (within 0-3 years) and long-term (>3- ~8 years) deaths, since studies show
15 that prediction of death may vary depending on the exposure being evaluated by more immediate
16 precipitating diseases, conditions or longer term exposures.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **METHODS**

31
32 **Study Population.** WIHS is a prospective, observational cohort suitable to study the intersection
33 of HIV-infection and aging. WIHS participants enrolled at six sites (Bronx/Manhattan, Brooklyn,
34 Chicago, Los Angeles, San Francisco and Washington DC); methods, and baseline cohort
35 characteristics have been described previously.¹⁴ Participants have visits every 6 months, which
36 include an extensive face-to-face interview by trained interviewers, medical examinations, and
37 laboratory specimen collection. Of the HIV-infected women actively enrolled in 2005, 1395
38 completed an assessment of the FFI. Of these, 1385 women reported current use of antiretroviral
39 therapy and had measures of both VACS index and CES-D and are included in the current
40 analyses.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Inclusion criteria.** Women included in these analyses are members of the WIHS cohort and had
4
5 to have adequately completed all indices (VACS, FFI, CES-D) in 2005 for evaluation in
6
7 association with mortality.
8
9

10
11
12 **Primary outcome.** Mortality over the ~8 years, 2005-2013 (also subcategorized into 0-3 and >3
13
14 - ~8 years) subsequent to measurement of the aging vulnerability indices, was the primary
15
16 outcome. The US National Death Index identified numbers and causes of death from Jan 1,
17
18 2005 through Dec 31, 2013. Causes of death were subdivided into AIDS and non-AIDS deaths
19
20 based on consensus opinion from a panel of WIHS investigators. (See Figure 1) AIDS deaths
21
22 included: pneumonia, PML, PCP, wasting syndrome, CNS lymphoma, candida, CMV,
23
24 Cryptococcus, toxoplasmosis, TB/mycobacterium, cervical cancer, pulmonary hypertension,
25
26 dementia/neurologic, renal failure, multi-organ failure and pancreatitis. Non-AIDS deaths
27
28 included: non-AIDS related malignancy, gastrointestinal, trauma, drug/alcohol overdose, heart
29
30 disease, lung disease, liver disease, kidney disease, neurologic/stroke, hemorrhage, pneumonia,
31
32 psychiatric, surgical complication, or pregnancy complication. For some, cause of death could
33
34 not be classified as AIDS or non-AIDS, thus the sum of these two subcategories is less than the
35
36 total number of deaths during the follow-up period.
37
38
39
40
41
42
43

44 **Primary Predictors of Death.** There were three primary predictors of interest: VACS score,
45
46 FFI, and CES-D score. The VACS Index facilitates a mortality risk score created by summing
47
48 pre-assigned points for age, routinely monitored indicators of HIV disease (CD4 count and HIV-
49
50 1 RNA), and viral hepatitis C infection (HCV); and general indicators of organ system injury
51
52 including hemoglobin, FIB-4, and estimated glomerular filtration rate, eGFR (ml/min). We
53
54
55
56
57

1
2
3 calculated eGFR based on the CKD-EPI equation.¹⁵ The VACS Index has a maximum score of
4
5 164. Our modified VACS Index (mVACS) totaled a maximum score of 136 since VACS age
6
7 groups were not included in our derivation of the algorithm due to the younger age of our sample
8
9 (VACS Index lowest age group is <50 years). Instead we adjusted for age as age decades that
10
11 reflected our sample as a separate covariate in multivariate analyses.
12
13
14
15

16
17 The FFI was defined using well-described criteria.⁷ A woman was classified as frail if she
18
19 exhibited three or more of five characteristics: 1) impaired mobility, 2) reduced grip strength, 3)
20
21 physical exhaustion, 4) unintentional weight loss and 5) low physical activity. At each site,
22
23 mobility was measured using a 3-4 meter timed gait test, and impaired mobility was defined as
24
25 the lowest quintile of performance among HIV negatives. Similarly, grip strength was measured
26
27 using a dominant hand-held dynamometer with maximum force; reduced grip strength was the
28
29 lowest quintile of performance among HIV negatives. Physical exhaustion was a “Yes” to the
30
31 question: “During the past four weeks, as a result of your physical health, have you had difficulty
32
33 performing your work or other activities (for example, it took extra efforts)?” Low physical
34
35 activity was a “Yes” to “Does your health now limit you in vigorous activities, such as running,
36
37 lifting heavy objects, or participating in strenuous sports?” Unintentional weight loss was a
38
39 “Yes” to: “Since your last visit, have you had unintentional weight loss of at least 10 pounds?”
40
41 If at least 3 components were available, the total out of 3 (or 4) was calculated.
42
43
44
45
46
47
48

49 The 20-item CES-D, is a depressive symptom screening tool. For these analyses, we excluded
50
51 two CES-D symptoms that overlap with the FFI. The excluded CES-D symptoms were ‘this past
52
53 week I could not get going’ (overlaps with low physical activity in the FFI) and ‘this past week
54
55
56
57

1
2
3 everything was an effort' (overlaps with exhaustion in the FFI). Thus, the maximum total points
4 possible on our modified CES-D (mCES-D) were 54 instead of 60), and a cut point of 15
5
6 (instead of the typical 16) was used to denote symptoms of clinical relevance.
7
8
9

10
11
12 **Statistical analyses.** We used single variable and multivariable proportional hazards models to
13 address the questions of which indices (of FFI, mVACS or mCES-D), when measured at mid-life
14 in this sample of HIV+ women, best predicted AIDS, non-AIDS and all death. Tested covariates
15 were those found to be significant in cross-sectional analyses.⁴ These covariates included
16 race/ethnicity, education, smoking, annual income, alcohol drinking, intravenous drug use (IDU)
17 history, body mass index (BMI), prior AIDS defining illness, pneumonia, cancer, diabetes and
18 hypertension. Methods for determining HIV and HCV infection status, Acquired
19 Immunodeficiency Syndrome (AIDS) diagnosis, CD4 cell count, HIV viral load, ART use, and
20 IDU were described previously.⁹ In addition, in relation to the frailty measures, we refit models
21 i) restricting follow up time to the first 3 years after measurement (i.e. censoring at 3 years), and
22 ii) starting follow up time at 3 years after the frailty measurement (i.e. truncating prior to 3
23 years). Results of proportional hazards regression models are presented as Hazards Ratios (HR)
24 with 95% Confidence Intervals (CI). The χ^2 statistic is also presented to facilitate comparison of
25 strength of association between models since the HR scale of each aging vulnerability index is
26 not the same. Data analyses were accomplished using SAS 9.4.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 RESULTS

50
51 Data were available for all indices on 1385 HIV+ women (average age 42.6 ± 8.8 years) who
52 reported ART use. The average mVACS score was 26.3 ± 18.2 (possible range 0-136);
53
54
55
56
57

1
2
3 prevalence of frailty (defined as FFI = 3-5) was 17.5%; and 37.3% had a mCES-D score of at
4 least 15 points indicating a clinically relevant depression phenotype. With regard to calculating
5 the FFI, of 1385 women, 1166 (84.2%) had no missing components, 94 (6.8%) had one missing
6 component and 125 (9.0%) had 2 missing components. The three indices, as well as individual
7 mVACS components, demographic/health behavior, infectious disease, chronic aging-related
8 disease variables, number and types of deaths are presented in Table 1. The crude HR (95% CI)
9 for all deaths by aging vulnerability indices and demographic/health behavior, infectious disease
10 and chronic aging-related disease variables are presented in Table 2. When evaluated separately
11 in univariate and multivariable models, worse (higher) FFI, mVACS, and mCES-D scores were
12 each significantly associated with a more rapid onset of mortality, as was higher age and several
13 other covariates.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Using multivariable models that included all indices, we separately evaluated all deaths up to ~8
32 years from baseline (Table 3) and subdivided by timing of death (short-term, 0 - 3 years vs long-
33 term, >3 to ~8 years from baseline, Table 4). We also modeled AIDS and non-AIDS deaths
34 separately over the same time periods. Over the entire follow-up period, FFI was a stronger
35 predictor of non-AIDS deaths than was the mVACS Index, while mVACS was a stronger
36 predictor of AIDS deaths than was FFI. Yet, all HR were significant for both indices. mCES-D
37 was not an independently significant predictor of death.
38
39
40
41
42
43
44
45
46
47
48

49 **All deaths.** When considering all deaths, within the first 3 years after baseline measurement
50 (Table 4A) the mVACS Index was the dominant, significant independent predictor of all deaths
51 (HR=2.21, 95% CI 1.84, 2.65, $\chi^2=72.50$, $p<0.0001$), followed by FFI (HR=2.11, 95% CI 1.23,
52
53
54
55
56
57

3.59, $\chi^2=7.46$, $p=0.0063$). For deaths occurring later than 3 years after baseline measures (Table 4B), the relative influence of the mVACS Index decreased (HR=1.59, 95% CI 1.33, 1.89, $\chi^2=26.75$, $p<0.0001$), and the FFI increased (HR=2.44, 95% CI 1.59, 3.73, $\chi^2=16.85$, $p<0.0001$).

AIDS deaths. Within 3 years after baseline (Table 4C), mVACS Index was the only statistically significant independent predictor (HR=3.27, 95% CI 2.53, 4.22, $\chi^2=82.38$, $p<0.0001$) of AIDS deaths; for AIDS death after 3 years (Table 4D), both mVACS Index (HR=1.80, 95% CI 1.34, 2.42, $\chi^2=15.49$, $p=0.0001$) and FFI (HR=3.27, 95% CI 1.53, 7.00, $\chi^2=9.28$, $p=0.002$) were independently significant.

Non-AIDS deaths. FFI was the most significant predictor of non-AIDS death both within (Table 3E) (HR=3.35, 95% CI 1.52, 7.35, $\chi^2=9.03$, $p=0.003$), and later (Table 4F) than 3 years post baseline (HR=3.11, 95% CI 1.62, 5.95, $\chi^2=11.66$, $p=0.0006$). The mVACS Index predicted death later than 3 years (HR=1.45, 95% CI 1.10, 1.92, $\chi^2=6.87$, $p=0.009$), but was not quite as robust as the FFI.

mCES-D score was not an independently significant (at $P < 0.05$) predictor in any AIDS or non-AIDS death model after adjusting for FFI and mVACS Index. Also of note, inclusion of ART-naïve participants ($n=54$, for a total N of 1439) did not change these findings.

DISCUSSION

We evaluated the ability of three common indices representing physical, biological and mental health status to predict mortality in adults with HIV infection. These indices - mVACS, a

1
2
3 biological HIV index; the FFI, a physical index; and the mCES-D, a mental health index - were
4
5 evaluated concurrently in association with mortality over approximately 8 years (and repeated
6
7 for 0-3 and >3 - ~8 years) among women with HIV infection. Overall, based on comparative χ^2
8
9 statistics, the mVACS Index was the strongest predictor of death, particularly of AIDS-related
10
11 deaths and early deaths within 3 years after index assessments. The FFI was also additively
12
13 informative, a better predictor of non-AIDS deaths than the mVACS and a relatively more
14
15 important predictor of deaths from 3 - ~ 8 years after index assessments.
16
17
18
19
20

21
22 First published in 2003, the FFI has been a useful construct by which to predict poor quality of
23
24 life, cognitive impairment, dementia and death.¹⁶ Ten years later, the first report on a validated
25
26 VACS index specific for those with HIV infection was published.⁵ The VACS Index has, since
27
28 then, been used to predict mortality in infected and uninfected populations and has been
29
30 associated with the FFI.⁶ In the WIHS, the VACS Index and CES-D score considered together
31
32 have been independently reported to predict mortality over a 5 year period.⁴ Here we show that
33
34 with addition of the FFI, these relationships change.
35
36
37
38
39

40
41 The FFI predicts death, particularly among elderly (65 years and older).¹⁰ More recently the FFI
42
43 has been measured in younger adult populations who may be at risk for premature or earlier
44
45 aging, such as those with HIV infection.^{6,17} These studies have shown that adults with HIV
46
47 infection, even in mid-life, experience a prevalence of frailty equivalent to, and greater than, that
48
49 observed in more elderly patients.^{4,9} The reason for this early manifestation of the frailty
50
51 phenotype may be a consequence of HIV infection itself, including suboptimal medication and
52
53 control of infection early on, comorbid diseases (infectious or non-infectious)^{4,18} and/or other
54
55
56
57
58
59
60

1
2
3 lifestyle habits that may be common among those with HIV infection, such as smoking and
4 substance use.¹¹ While interesting, FFI fluctuations cannot be addressed in these analyses, but
5
6 will be in the future with the re-initiation of FFI assessments in the WIHS in Fall 2015. As the
7
8 FFI is a marker of the slower process of physical aging, it may continue to be more strongly
9
10 associated with non-AIDS and later deaths as was seen in this analysis.
11
12
13
14
15

16
17 The mCES-D was significantly associated with death in models that did not adjust for mVACS
18 and FFI (i.e. $p=0.0017$ and $\chi^2=9.9$ in Table 2), however it was not associated with death once
19 mVACS and FFI indices were included in the same model. Several studies that do not consider
20 FFI and/or VACS, including those from the WIHS, have found CES-D to be a significant
21 “independent” predictor of mortality.^{4,19-23} This study calls into question whether CES-D is a
22 surrogate for other vulnerabilities rather than being independently causally associated with death.
23
24 Other studies or analyses of CES-D in relation to death tend to not include other frailty indices in
25 their models or only include VACS.⁴ It should be noted that our mCES-D excludes two items
26 overlapping with the FFI (low physical activity and exhaustion). However, adding these two
27 items back to the mCES-D did not qualitatively change the failure of CES-D to be significant in
28 the multivariate models (data not shown). Evaluating vulnerabilities in middle-aged HIV-
29 infected women (the average age of infected women today) is important to understanding the
30 impact of HIV infection on mortality over the life course. This approach has been shown for
31 other diseases of later-life.²⁴ Midlife physical, biological and/or mental indicators against the
32 background of HIV infection may be associated with earlier death.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Why are multi-dimensional frailty indices associated with mortality in adults with HIV
4 infection? Throughout adult life, HIV infection is synergistic with adverse aging influences on
5 the immune, vascular, reproductive, and central nervous systems, thereby intensifying the aging
6 process.^{25,26} In our previous cross-sectional analysis of the FFI, we showed that the FFI is
7 associated with infectious, demographic, chronic disease, and biological factors, including
8 individual components of the VACS Index,⁴ lending support to this observation.
9
10
11
12
13
14
15
16
17
18

19 We chose to assess deaths occurring within 3 years versus those occurring ≥ 3 years after the
20 indices were measured. Studies in uninfected populations have shown that deaths occurring
21 within a short period of time (e.g., 3 years) tend to be those due to more rapid biological triggers
22 of death such as infections (e.g., HIV, pneumonia) or other acute illnesses, while longer term
23 deaths reflect delayed consequences of deteriorating biological and physical health.²⁷ Non-AIDS
24 deaths were predicted by FFI, whether those deaths occurred within or later than 3 years.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

44 Aging with HIV infection is associated with geriatric morbidities or syndromes, including
45 frailty,²⁸ however these aging morbidities often occur earlier among those with HIV infection
46 compared to uninfected individuals.²⁹⁻³¹ The question is whether HIV infection leads to more
47 severe aging phenotypes, or accelerates their onset leading to earlier age of death.³² These
48 analyses show that two indices, the mVACS (biological) index and the FFI (physical),
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 independently predict mortality in middle-aged women with HIV infection. Inclusion of mCES-
4
5 D, a depressive symptom scale, was not independently informative once both the biological and
6
7 physical frailty measures were considered. This is the first published report on the simultaneous
8
9 evaluation of these important indices in association with mortality in women with HIV infection.
10
11 These analyses point to the importance of designing interventions to address components of
12
13 multifaceted indices in the hopes of extending the lifespan of patients living with chronic HIV.
14
15

16 17 18 19 **Author Contributions**

20
21 All authors contributed to this work. Hypothesis generation and manuscript drafting was led by
22
23 DG and DH; statistical analyses and interpretation was led by DH and QS; participant
24
25 recruitment and retention were accomplished by the WIHS Principal Investigators, DG, HM,
26
27 MC, MP, AS, SG, MG, and JM and project staff, SH. Manuscript editing was performed by all.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding Statement

Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff, Deborah Gustafson); Washington DC, Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590) and by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (U01-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Data collection was supported by a dissertation grant through the National Institute of Drug Abuse (1R36DA021104-01). In addition, Dr. Gustafson received support from NIH/NIAID ARRA Supplement No. 54492, Swedish Research Council for Health, Working Life and Welfare (AGECAP 2013-2300) and the SUNY Research Foundation.

The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

We thank the women participating in WIHS for their time, cooperation, and support.

Competing Interest

There are no competing interests to declare.

STROBE Criteria

This manuscript meets the STROBE criteria for longitudinal cohort studies.

Data Sharing

Technical appendix, statistical code, and dataset are available from the WIHS Statistical Analysis Center, WD-MAC.

For peer review only

REFERENCES

1. Kirk JB, Goetz MB. Human immunodeficiency virus in an aging population, a complication of success. *Journal of the American Geriatrics Society* 2009; **57**(11): 2129-38.
2. Vance DE, McGuinness T, Musgrove K, Orel NA, Fazeli PL. Successful aging and the epidemiology of HIV. *Clin Interv Aging* 2011; **6**: 181-92.
3. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. *PloS one* 2013; **8**(12): e81355.
4. Cohen MH, Hotton AL, Hershow RC, et al. Gender-related risk factors improve mortality predictive ability of VACS Index among HIV-infected women. *J Acquir Immune Defic Syndr* 2015.
5. Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. *J Acquir Immune Defic Syndr* 2013; **62**(2): 149-63.
6. Escota GV, Patel P, Brooks JT, et al. Short communication: The Veterans Aging Cohort Study Index is an effective tool to assess baseline frailty status in a contemporary cohort of HIV-infected persons. *AIDS research and human retroviruses* 2015; **31**(3): 313-7.
7. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *The journals of gerontology Series A, Biological sciences and medical sciences* 2001; **56**(3): M146-56.
8. Rizzoli R, Reginster JY, Arnal JF, et al. Quality of life in sarcopenia and frailty. *Calcif Tissue Int* 2013; **93**(2): 101-20.
9. Terzian AS, Holman S, Nathwani N, et al. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. *J Womens Health (Larchmt)* 2009; **18**(12): 1965-74.
10. Shamliyan T, Talley KM, Ramakrishnan R, Kane RL. Association of frailty with survival: a systematic literature review. *Ageing Res Rev* 2013; **12**(2): 719-36.
11. Piggott DA, Muzaale AD, Mehta SH, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. *PloS one* 2013; **8**(1): e54910.
12. Ravindrarajah R, Lee DM, Pye SR, et al. The ability of three different models of frailty to predict all-cause mortality: Results from the European Male Aging Study (EMAS). *Archives of gerontology and geriatrics* 2013; **57**(3): 360-8.
13. Andrew MK, Fisk JD, Rockwood K. Psychological well-being in relation to frailty: a frailty identity crisis? *International psychogeriatrics / IPA* 2012; **24**(8): 1347-53.
14. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. *Clin Diagn Lab Immunol* 2005; **12**(9): 1013-9.
15. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; **150**(9): 604-12.
16. Hirsch C, Anderson ML, Newman A, et al. The association of race with frailty: the cardiovascular health study. *Annals of epidemiology* 2006; **16**(7): 545-53.
17. Erlandson KM, Schrack JA, Jankowski CM, Brown TT, Campbell TB. Functional impairment, disability, and frailty in adults aging with HIV-infection. *Curr HIV/AIDS Rep* 2014; **11**(3): 279-90.
18. Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. *Infection* 2004; **32**(1): 33-46.

19. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. *The American journal of medicine* 2002; **113**(2): 91-8.
20. Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. *Am J Public Health* 2004; **94**(7): 1133-40.
21. Coughlin SS. Invited commentary: Prevailing over acquired immune deficiency syndrome and depressive symptoms. *American journal of epidemiology* 2013; **177**(2): 126-8; discussion 9-30.
22. Farinpour R, Miller EN, Satz P, et al. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). *J Clin Exp Neuropsychol* 2003; **25**(5): 654-70.
23. Lyketsos CG, Hoover DR, Guccione M, et al. Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study. *JAMA* 1993; **270**(21): 2563-7.
24. Ritchie K, Ritchie CW, Yaffe K, Skoog I, Scarmeas N. Is late-onset Alzheimer's disease really a disease of midlife? *Translational Res Clin Interventions* 2015; **1**: 122-30.
25. Nguyen N, Holodniy M. HIV infection in the elderly. *Clin Interv Aging* 2008; **3**(3): 453-72.
26. Kalayjian RC, Landay A, Pollard RB, et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. *J Infect Dis* 2003; **187**(12): 1924-33.
27. Gustafson DR, Mazzuco S, Ongaro F, et al. Body mass index, cognition, disability, APOE genotype, and mortality: the "Treviso Longeva" Study. *Am J Geriatr Psychiatry* 2012; **20**(7): 594-602.
28. Greene M, Covinsky KE, Valcour V, et al. Geriatric Syndromes in Older HIV-Infected Adults. *J Acquir Immune Defic Syndr* 2015; **69**(2): 161-7.
29. Desquilbet L, Jacobson LP, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. *The journals of gerontology Series A, Biological sciences and medical sciences* 2007; **62**(11): 1279-86.
30. Desquilbet L, Jacobson LP, Fried LP, et al. A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. *The journals of gerontology Series A, Biological sciences and medical sciences* 2011; **66**(9): 1030-8.
31. Desquilbet L, Margolick JB, Fried LP, et al. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. *J Acquir Immune Defic Syndr* 2009; **50**(3): 299-306.
32. Onen NF, Overton ET. A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging. *Current aging science* 2011; **4**(1): 33-41.

Table 1. Baseline characteristics of HIV-infected WIHS participants who are not ART-naive

Variables	N (%)
Indices	
Fried Frailty Index (FFI)	
0-2	1143 (82.5)
3-5	242 (17.5)
mVACS Score (0-136) ^a	26.3 ±18.2
mCES-D score ≥ 15 ^b	
No	869 (62.9)
Yes	516 (37.1)
Outcomes	
All Deaths	
3 Years or Less	73 (5.3)
> 3-8 years	111 (8.0)
AIDS deaths ^c	
3 Years or Less	39 (2.8)
> 3-8 years	35 (2.5)
Non-AIDS deaths ^c	
3 Years or Less	32 (2.3)
> 3-8 years	45 (3.2)
HIV variables	
CD4 count (cells/mm ³)	
≥ 500	554 (40.0)
200-499	614 (44.3)
< 200	217 (15.7)
Viral Load (copies/ml)	
< 500	820 (59.2)
500-100,000	510 (36.8)
>100,000	55 (4.0)
Hemoglobin (g/dl)	
≥14	209 (15.1)
12-13.9	743 (53.6)
10-11.9	362 (26.1)
<10	71 (5.1)
FIB4	
< 1.45	1018 (73.5)
1.45-3.25	280 (20.2)
> 3.25	87 (6.3)
eGFR (ml/min)	
≥60	1277 (92.2)
45-59.9	71 (5.1)
30-44.9	15 (1.1)
< 30	22 (1.6)
Hepatitis C Co-infection	298 (21.5)

Demographic Variables

Average age (years, mean \pm SD)	42.6 \pm 8.8
Race/Ethnicity	
White	324 (23.4)
Black	806 (58.2)
Others	255 (18.4)
Education	
< High School	536 (38.7)
\geq High School	847 (61.2)
Mission	2 (0.1)
Smoking History	
Not current smoking	786 (56.8)
Current smoking	599 (43.2)
Income	
< \$12,000	669 (48.3)
\geq \$12,000	668 (48.2)
Missing	48 (3.5)
Current Alcohol Drinking	
Abstainer/None	743 (53.6)
Low	490 (35.4)
Moderate	129 (9.3)
High	23 (1.7)
Body Mass Index (BMI), kg/m ²	
BMI < 30	916 (66.1)
BMI \geq 30 (Obesity)	461 (33.3)
Missing	8 (0.6)
Current ART use	
No	400 (28.9)
Yes (HAART)	984 (71.0)
Missing	1 (0.1)
Prior AIDS Defining Illness	
No	802 (57.9)
Yes	583 (42.1)
Injection Drug Use Ever	
Yes	305 (22.0)
No	1071 (77.3)
Missing	9 (0.6)
Prior Pneumonia	
No	1080 (78.0)
Yes	305 (22.0)
Current / Prior Hypertension	
No	964 (69.6)
Yes	421 (30.4)
History of Diabetes	

No	1195 (86.3)
Yes	190 (13.7)
Prior Cancer Diagnosis	
No	1220 (88.1)
Yes	165 (11.9)

^amVACS Index without VACS-specific age strata; usual sum is 163, without age category the maximum possible sum is 136. The VACS Index includes older age groups not adequately represented in the WIHS. Thus, we adjust for age category in the analysis and leave age group out of the VACS score, resulting in a lower total VACS score.

^bmCES-D is a CES-D score calculated without inclusion of 2 items that could overlap with FFI

^cFor some deaths, cause of death could not be classified as AIDS / non-AIDS, thus the number of AIDS + non-AIDS deaths does not sum to total deaths.

Table 2. Proportional Hazards models of time to all deaths by FFI, mVACS, mCESD, age group, and potential confounders among women with HIV infection

Variable	Crude HR (95% CI)	χ^2	P-value
Univariate Analyses of Indices			
mVACS Score (0-136), per 20 units ^a	2.21 (1.99, 2.46)	209.7	< 0.0001
FFI 3-5 vs 0-2	3.92 (2.92, 5.26)	83.2	< 0.0001
mCESD, modified (< 15 vs \geq 15) ^b	2.01 (1.50, 2.68)	22.2	<0.0001
Univariate Analyses of Potential Confounders			
Age per Decade	1.62 (1.38, 1.89)	36.14	<0.0001
Race/ethnicity		8.95 (2 df)	0.011
White vs black	0.55 (0.37, 0.83)	8.02	0.005
Others vs black	0.74 (0.49, 1.11)	2.15	0.140
Education \geq high school vs < high school	0.68 (0.51, 0.90)	6.96	0.008
Smoking (current vs no)	3.41 (2.49, 4.69)	57.5	<0.0001
Income (< \$12,000 vs \geq \$12,000)	2.03 (1.49, 2.77)	19.8	<0.0001
Drinking		27.25 (3 df)	<0.0001
Low vs Abstainer/None	0.59 (0.42, 0.84)	8.59	0.003
Moderate vs Abstainer/None	1.27 (0.82, 1.98)	1.14	0.290
High vs Abstainer/None	3.48 (1.76, 6.87)	12.9	0.0003
BMI, kg/m ² (\geq 30 vs <30)	0.57 (0.41, 0.81)	10.2	0.001

^amVACS Index score without VACS-specific age strata; ^bmCES-D without FFI overlap

Table 3. mVACS Index, FFI, and mCES-D individually predict time to all, AIDS and non-AIDS deaths over ~8 years follow-up among women with HIV infection.

Index	All deaths			AIDS deaths			Non-AIDS deaths		
	X2	HR ^c (95% CI)	P-value	X2	HR (95% CI)	P-value	X2	HR (95% CI)	P-value
FFI	26.15	2.36 (1.79, 3.28)	< 0.0001	9.76	2.34 (1.37, 3.98)	0.002	20.806	3.20 (1.94, 5.26)	< 0.0001
mVACS ^a	97.07	1.85 (1.64, 2.09)	< 0.0001	100.12	2.54 (2.12, 3.05)	0.000	7.0126	1.33 (1.08, 1.65)	0.008
mCES-D ^b	1.84	1.24 (0.91, 1.70)	0.188	4.29	1.75 (1.03, 2.96)	0.038	0.0211	0.96 (0.59, 1.57)	0.885
Age per decade	10.22	1.37 (1.13, 1.66)	0.001	0.0027	0.99 (0.72, 1.36)	0.959	11.133	1.63 (1.22, 2.17)	0.001

^amVACS Index score without VACS-specific age strata

^bmCES-D is a CES-D score calculated without inclusion of 2 items that could overlap with FFI

^cMultivariate models included race/ethnicity; education less than or equal to vs greater than high school; smoking current vs no; income less than vs greater than or equal to \$12,000 annually; drinking low, moderate or high vs none; and BMI at least than vs less 30 kg/m²

Table 4. Multivariable proportional hazards models of time to all, AIDS and non-AIDS deaths within 3 years vs greater than 3 years by mVACS Index, FFI, mCES-D and age among women with HIV infection.

Variable	A. All Deaths Within 3 Years After FFI Visit			B. All Deaths Later Than 3 Years After FFI Visit		
	χ^2	Multivariate-Adjusted HR ^b (95% CI)	P-value	χ^2	Multivariate-Adjusted HR ^b (95% CI)	P-Value
mVACS Index per 20	72.50	2.21 (1.84, 2.65)	0.0000	26.75	1.59 (1.33, 1.89)	<0.0001
FFI (3-5 vs 0-2)	7.46	2.11 (1.23, 3.59)	0.006	16.85	2.44 (1.59, 3.73)	<0.0001
mCES-D ^c (< 15 vs ≥15)	1.74	1.42 (0.84, 2.40)	0.187	0.35	1.13 (0.75, 1.69)	0.550
Age per Decade	3.23	1.33 (0.97, 1.83)	0.072	7.89	1.42 (1.11, 1.82)	0.005
	C. AIDS Deaths Within 3 Years or Less After FFI Visit			D. AIDS Deaths Later Than 3 Years After FFI Visit		
	χ^2	Multivariate-Adjusted HR ^b (95% CI)	P-value	χ^2	Multivariate-Adjusted HR ^b (95% CI)	P-Value
mVACS Index per 20	82.38	3.27 (2.53, 4.22)	0.0000	15.49	1.80 (1.34, 2.42)	0.0001
FFI (3-5 vs 0-2)	1.88	1.68 (0.80, 3.54)	0.171	9.28	3.27 (1.53, 7.00)	0.002
mCES-D ^c (< 15 vs ≥15)	2.25	1.75 (0.84, 3.64)	0.133	2.13	1.76 (0.82, 3.78)	0.140
Age per Decade	0.001	0.99 (0.64, 1.54)	0.971	0.14	1.10 (0.68, 1.76)	0.710
	E. Non-AIDS Deaths Within 3 Years or Less After FFI Visit			F. Non-AIDS Deaths Later Than 3 Years After FFI Visit		
	χ^2	Multivariate-Adjusted HR ^b (95% CI)	P-value	χ^2	Multivariate-Adjusted HR ^b (95% CI)	P-Value
mVACS Index per 20	0.87	1.17 (0.84, 1.65)	0.350	6.87	1.45 (1.10, 1.92)	0.009


FFI (3-5 vs 0-2)	9.03	3.35 (1.52, 7.35)	0.003	11.66	3.11 (1.62, 5.95)	0.0006
mCES-D ^c (< 15 vs >=15)	0.16	1.17 (0.54, 2.52)	0.690	0.23	0.86 (0.45, 1.62)	0.630
Age per Decade	9.25	2.00 (1.28, 3.14)	0.002	2.89	1.38 (0.95, 2.01)	0.089

^amVACS Index score without VACS-specific age strata

^bMultivariate models included race/ethnicity; education less than or equal to vs greater than high school; smoking current vs no; income less than vs greater than or equal to \$12,000 annually; drinking low, moderate or high vs none; and BMI at least than vs less 30 kg/m²

^cmCES-D is a CES-D score calculated without inclusion of 2 items that could overlap with FFI

Figure 1. WIHS participants with mVACS, FFI, and mCES-D measured in 2005 and follow-up over approximately 8 years



****All items in the STROBE checklist have been accomplished.**

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Predicting death over 8 years in a prospective cohort of HIV-infected women. The Women's Interagency HIV Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013993.R1
Article Type:	Research
Date Submitted by the Author:	01-Mar-2017
Complete List of Authors:	Gustafson, Deborah R.; Suny Downstate Med Ctr, Neurology Shi, Qiuhu; New York Medical College School of Health Sciences and Practice, Epidemiology and Community Health Holman, Susan; SUNY Downstate Medical Center College of Medicine, Medicine Minkoff, Howard; Maimonides Medical Center, Cohen, Mardge; Rush University, Medicine Plankey, PhD, Michael; Georgetown University, Infectious Disease Epidemiology Havlik, MD, MPH, Richard; Arrow Health, Internal Medicine Sharma, Anjali; Yeshiva University Albert Einstein College of Medicine, Epidemiology Infectious Disease Gange, Stephen ; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Gandhi, Monica; University of California San Francisco School of Medicine, Infectious Disease Milam, Joel; Keck School of Medicine of the University of Southern California, Preventive Medicine Hoover, Donald; The State University of New Jersey, Department of Statistics
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Epidemiology, Infectious diseases, Neurology, Geriatric medicine, Mental health
Keywords:	Frailty, HIV, HCV, Aging

SCHOLARONE™
Manuscripts

1
2
3 **Predicting death over 8 years in a prospective cohort of HIV-infected women. The**
4
5 **Women's Interagency HIV Study**
6
7
8
9

10 Deborah R. Gustafson, MS, PhD^a; Qiuhu Shi, PhD^b; Susan A. Holman, RN, MS^c; Howard
11 Minkoff, MD^{d,e}; Mardge H. Cohen, MD^f; Michael W. Plankey, PhD^g; Richard Havlik, MD,
12 MPH^h; Anjali Sharma, MD, MSⁱ; Stephen Gange, PhD^j; Monica Gandhi, MD^k; Joel Milam PhD^l;
13
14
15
16
17 Donald R. Hoover MPH, PhD^m
18
19
20
21

22 ^aDepartment of Neurology, State University of New York - Downstate Medical Center,
23 Brooklyn, NY; ^bSchool of Health Sciences and Practice, New York Medical College, Valhalla,
24 NY; ^cDepartment of Medicine, State University of New York - Downstate Medical Center;
25
26
27
28
29 ^dMaimonides Medical Center, Brooklyn, NY; ^eDepartment of Obstetrics and Gynecology, State
30 University of New York - Downstate Medical Center, Brooklyn, NY; ^fDepartments of Medicine,
31 Stroger Hospital of Cook County Health and Hospital System and Rush University; ^gDepartment
32 of Medicine, Division of Infectious Diseases, Georgetown University Medical Center; ^hAIDS
33 Community Research in American, New York, NY; ⁱDepartment of Medicine, Albert Einstein
34 College of Medicine, Bronx, NY; ^jDepartment of Epidemiology, Johns Hopkins Bloomberg
35 School of Public Health, Baltimore, MD; ^kDepartment of Medicine, University of California, San
36 Francisco (UCSF); ^lDepartment of Preventive Medicine, University of Southern California;
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Deborah R. Gustafson, PhD, MS (corresponding author)

1
2
3 Professor, Department of Neurology
4

5
6 SUNY Downstate Medical Center
7

8
9 450 Clarkson Ave, MSC 1213
10

11
12 Brooklyn, NY 11203
13

14
15 deborah.gustafson@downstate.edu
16

17
18 718-270-1581
19

20
21 Running head: Frailty in HIV+/HIV- women
22

23
24 **Key Words:** Frailty, HIV, HCV, Aging
25

26
27 DISCLOSURE STATEMENT: The authors have nothing to disclose.
28

29
30 Abstract Word Count: 218/250 allowed
31

32
33 Text Word Count: 3323
34

35
36 1 Figure, 5 tables
37

38
39 References: 35
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives. Predicting mortality in middle-aged HIV-infected (HIV+) women on antiretroviral therapies (ART) is important for understanding the impact of HIV infection. Several health indices have been used to predict mortality in women with HIV infection. We evaluated: 1) an HIV biological index, Veterans Aging Cohort Study (VACS); 2) a physical index, Fried Frailty Index (FFI); and 3) a mental health index, Centers for Epidemiologic Studies-Depression (CES-D). Proportional hazards regression analyses were used to predict death and included relevant covariates.

Design. Prospective, observational cohort

Setting. Multicenter, across 6 sites in the United States

Participants. 1385 multirace/ethnic HIV+ women on ART in 2005

Primary and secondary outcomes. All deaths, AIDS-deaths and non-AIDS deaths up to ~8 years from baseline

Results. Included together in one model, VACS Index was the dominant, significant independent predictor of all deaths within 3 years (HR=2.20, 95% CI 1.83, 2.65, $\chi^2=69.04$, $p<0.0001$), and later than 3 years (HR=1.55, 95% CI 1.30, 1.84 $X^2=23.88$, $p<0.0001$); followed by FFI within 3 years (HR=2.06, 95% CI 1.19, 3.57, $\chi^2=6.73$, $p=0.01$) and later than 3 years (HR=2.43, 95% CI 1.58, 3.75, $X^2=16.18$, $p=0.0001$). CES-D score was not associated with mortality.

Conclusions and Relevance. This is the first simultaneous evaluation of three common health indices in HIV infected adults. Indices reflecting physical and biological aging were associated with death.

Article summary

Strengths and limitations of this study

- Longitudinal cohort study with follow-up of almost 10 years
- Well-phenotyped White, African American and Latina HIV+ women
- Reputable standardized and validated physical, biological and emotional health indices
- Somewhat limited generalizability since a survivor sample of urban women with strong, consistent research study-related HIV care and social support
- Health indices and mortality were examined at mid-life, a period when risk of death is low.

INTRODUCTION

HIV infection continues as a major global health issue affecting approximately 36 million people worldwide. HIV infection has evolved from a fatal infection to a treatable, chronic condition of aging,^{1,2} accompanied by multiple morbidities and rising healthcare costs. The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), observed that life expectancy of HIV infected (HIV+) adults increased from 36 to 51 years between 2000 and 2007,³ primarily due to treatment advances. In 2015, over half of HIV+ Americans are ≥ 50 years old.³ Therefore, HIV infection may prove to represent a modern-day phenomenon of achieving healthy old age accompanied by improved longevity.

Predicting death in chronic HIV infection may assist in the design of interventions to understand, prevent, cure or minimize age-related impairments, improve health and increase lifespan. Several health indices predict death in adults with HIV infection - the Veterans Aging Cohort Study (VACS) Index; Fried Frailty Index (FFI); and the Centers for Epidemiologic Studies – Depression (CES-D) score. These indices represent biological, physical and mental health vulnerabilities that worsen with age. The only HIV-specific mortality index is the VACS Index, which has been reproduced in North American and European patient populations including Highly Active ART (HAART) users in the Women's Interagency HIV Study (WIHS).^{4,5} The VACS Index creates a clinical HIV mortality risk score by summing pre-assigned points for age, routinely monitored indicators of HIV disease and general indicators of organ system function.^{5,6} The FFI is most commonly used when describing aging in both general and HIV+ populations.^{7,8} Frailty is a common co-morbidity of HIV infection, observed even during middle age.^{4,9} The FFI includes measures of gait speed, handgrip strength, body weight loss, physical activity, and exhaustion and predicts death.¹⁰⁻¹² The Centers for Epidemiologic Studies – Depression (CES-D)

1
2
3 score measures mental health¹³ and has been independently associated with mortality,
4 particularly among women with HIV infection on HAART in the WIHS.⁴
5
6
7
8
9

10 The objective of our analyses was to evaluate, among HIV+ women, the association of the
11 aforementioned, frequently used health indices: VACS, FFI, and CES-D, with death (both AIDS-
12 and non-AIDS related). All indices were measured in mid-life (average age 39 years) in our
13 analyses and evaluated for prediction of mortality for up to ~8 years. This follow-up period was
14 further broken down into short-term (within 0-3 years) and long-term (>3- ~8 years) deaths,
15 since studies show that prediction of death may vary depending on the exposure being evaluated
16 in relation to more immediate precipitating diseases or conditions versus chronic outcomes.
17
18
19
20
21
22
23
24
25
26
27
28

29 **METHODS**

30
31 **Study Population.** WIHS is a prospective, observational cohort suitable to study the intersection
32 of HIV-infection and aging. WIHS participants enrolled at six sites (Bronx/Manhattan, Brooklyn,
33 Chicago, Los Angeles, San Francisco and Washington DC); methods, and baseline cohort
34 characteristics have been described previously.¹⁴ Participants have visits every 6 months, which
35 include an extensive face-to-face interview by trained interviewers, medical examinations, and
36 laboratory specimen collection. Written informed consent was provided by all WIHS participants
37 via human subjects protocols that were approved by institutional review committees at each
38 affiliated institution (Albert Einstein College of Medicine and Montefiore Medical Center
39 Institutional Review Board, #03-07-174; Cook County Bureau of Health Services Institutional
40 Review Board, #15-084; Georgetown University Institutional Review Board Protocol #1993-
41 077; State University of New York - Downstate Medical Center Institutional Review Board,
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 #266921; University of California San Francisco Committee on Human Research, #1003720;
4
5 and University of Southern California Institutional Review Board HS-944027.
6
7
8
9

10 Of the HIV+ women actively enrolled in 2005, 1395 completed an assessment of the FFI. Of
11 these, 1385 women reported current use of antiretroviral therapy and had measures of both
12 VACS index and CES-D and are included in the current analyses.
13
14
15
16
17
18
19

20 **Inclusion criteria.** Women included in these analyses are members of the WIHS cohort and had
21 to have adequately completed all indices (VACS, FFI, CES-D) in 2005 for evaluation in
22 association with mortality.
23
24
25
26
27
28

29 **Primary outcome.** Mortality over the ~8 years, 2005-2013 (also subcategorized into 0-3 and >3
30 - ~8 years) subsequent to measurement of the aging vulnerability indices, was the primary
31 outcome. The US National Death Index identified numbers and causes of death from Jan 1, 2005
32 through Dec 31, 2013. Causes of death were subdivided into AIDS and non-AIDS deaths based
33 on consensus opinion from a panel of WIHS investigators.¹⁵ (See Figure 1) AIDS deaths
34 included: pneumonia, PML, PCP, wasting syndrome, CNS lymphoma, candida, CMV,
35 Cryptococcus, toxoplasmosis, TB/mycobacterium, cervical cancer, pulmonary hypertension,
36 dementia/neurologic, renal failure, multi-organ failure and pancreatitis. Non-AIDS deaths
37 included: non-AIDS related malignancy, gastrointestinal, trauma, drug/alcohol overdose, heart
38 disease, lung disease, liver disease, kidney disease, neurologic/stroke, hemorrhage, pneumonia,
39 psychiatric, surgical complication, or pregnancy complication. For some, cause of death could
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 not be classified as AIDS or non-AIDS, thus the sum of these two subcategories is less than the
4
5 total number of deaths during the follow-up period.
6
7

8
9
10 **Primary Predictors of Death.** There were three primary predictors of interest: VACS score,
11
12 FFI, and CES-D score. The VACS Index facilitates a mortality risk score created by summing
13
14 pre-assigned points for age, routinely monitored indicators of HIV disease (CD4 count and HIV-
15
16 1 RNA), and viral hepatitis C infection (HCV); and general indicators of organ system injury
17
18 including hemoglobin, FIB-4, and estimated glomerular filtration rate, eGFR (ml/min). We
19
20 calculated eGFR based on the CKD-EPI equation.¹⁶ The VACS Index has a maximum score of
21
22
23
24
25 164.
26
27

28
29 The FFI was defined using well-described criteria.⁷ A woman was classified as frail if she
30
31 exhibited three or more of five characteristics: 1) impaired mobility, 2) reduced grip strength, 3)
32
33 physical exhaustion, 4) unintentional weight loss and 5) low physical activity. At each site,
34
35 mobility was measured using a 3-4 meter timed gait test, and impaired mobility was defined as
36
37 the lowest quintile of performance among HIV negatives. Similarly, grip strength was measured
38
39 using a dominant hand-held dynamometer with maximum force; reduced grip strength was the
40
41 lowest quintile of performance among HIV negatives. Physical exhaustion was a “Yes” to the
42
43 question: “During the past four weeks, as a result of your physical health, have you had difficulty
44
45 performing your work or other activities (for example, it took extra efforts)?” Low physical
46
47 activity was a “Yes” to “Does your health now limit you in vigorous activities, such as running,
48
49 lifting heavy objects, or participating in strenuous sports?” Unintentional weight loss was a
50
51
52
53
54
55
56
57
58
59
60

1
2
3 “Yes” to: “Since your last visit, have you had unintentional weight loss of at least 10 pounds?”
4

5
6 If at least 3 components were available, the total out of 3 (or 4) was calculated.
7
8
9

10 The 20-item CES-D, is a depressive symptom screening tool comprised of 20 items and totaling
11
12 60 points. A cut point of 16 was used to denote a symptom burden of clinical relevance.¹⁷
13
14

15
16
17 **Statistical analyses.** We used single variable and multivariable proportional hazards models to
18
19 address the questions of which indices (of FFI, VACS or CES-D), when measured at mid-life in
20
21 this sample of HIV+ women, best predicted AIDS, non-AIDS and all death. Concordance
22
23 statistics (C-statistics) were also calculated. Besides FFI, VACS and CES-D, tested covariates
24
25 were those found to be significant in cross-sectional analyses.⁴ These covariates included
26
27 race/ethnicity, education, smoking, annual income, alcohol drinking, intravenous drug use (IDU)
28
29 history, body mass index (BMI), prior AIDS defining illness, pneumonia, cancer, diabetes and
30
31 hypertension. Methods for determining HIV and HCV infection status, Acquired
32
33 Immunodeficiency Syndrome (AIDS) diagnosis, CD4 cell count, HIV viral load, ART use, and
34
35 IDU were described previously.⁹ In addition, in relation to the health indices, we refit models i)
36
37 restricting follow up time to the first 3 years after measurement (i.e. censoring at 3 years), and ii)
38
39 starting follow up time at 3 years after the health indices measurements (i.e. truncating prior to 3
40
41 years). In addition, the interaction between FFI and CES-D was considered. Results of
42
43 proportional hazards regression models are presented as Hazards Ratios (HR) with 95%
44
45 Confidence Intervals (CI). The χ^2 statistic is also presented to facilitate comparison of strength of
46
47 association between models since the HR scale of each aging vulnerability index is not the same.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Data analyses were accomplished using SAS 9.4 C-statistics were calculated using STATA
4
5 Version 12.1.
6
7
8
9

10 *Modified VACS and CES-D Indices.* While not reported here, as a sensitivity analysis, we reran
11 the statistical models using a modified VACS Index and a modified CES-D. Our modified
12 VACS Index did not include VACS age groups in the derivation of total points due to the
13 younger age of our sample (VACS Index lowest age group is <50 years). Thus, a maximum
14 score of 136 was attainable. We then adjusted for age as age decades that reflected our sample as
15 a separate covariate in multivariate analyses. Our modified CES-D score resulted from
16 excluding two CES-D symptoms that overlap with the FFI. The excluded CES-D symptoms were
17 ‘this past week I could not get going’ (overlaps with low physical activity in the FFI) and ‘this
18 past week everything was an effort’ (overlaps with exhaustion in the FFI).
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 RESULTS

35
36 Data were available for all indices on 1385 HIV+ women (average age 42.6 ± 8.8 years) who
37 reported ART use. The average VACS score was 28.9 ± 19.4 (possible range 0-164); prevalence
38 of frailty (defined as FFI = 3-5) was 17.5%; and 39.1% had a CES-D score of at least 16 points
39 indicating a clinically relevant depressive symptom burden. With regard to calculating the FFI,
40 of 1385 women, 1166 (84.2%) had no missing components, 94 (6.8%) had one missing
41 component and 125 (9.0%) had 2 missing components. The three indices, as well as individual
42 VACS components, demographic/health behavior, infectious disease, chronic aging-related
43 disease variables, number and types of deaths are presented in Table 1. The crude HR (95% CI)
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 for all deaths by aging vulnerability indices and demographic/health behavior, infectious disease
4
5 and chronic aging-related disease variables are presented in Table 2.
6
7
8
9

10 *C-Statistics.* When evaluated in multivariable models, worse (higher) FFI, VACS, and CES-D
11
12 scores were each significantly associated with a more rapid onset of mortality, additive to higher
13
14 age and several other covariates (Table 3). As a single index added on to demographics, the
15
16 VACS performed best for all and AIDS deaths, however the FFI was best for non-AIDS deaths.
17
18 The C-statistics were qualitatively higher for AIDS death reaching 0.89 with demographics and
19
20 VACS in the model and remaining at 0.89 in the full model than for non-AIDS death which
21
22 reached 0.80 with VACS and FFI in the model and only improving to 0.81 in the full model.
23
24
25
26
27
28

29 Using multivariable models that included all indices, we separately evaluated all deaths up to ~8
30
31 years from baseline (Table 4) and subdivided by timing of death (short-term, 0 - 3 years vs long-
32
33 term, >3 to ~8 years from baseline, Table 5). We also modeled AIDS and non-AIDS deaths
34
35 separately over the same time periods. Over the entire follow-up period, FFI was a stronger
36
37 predictor of non-AIDS deaths than was the VACS Index, while VACS was a stronger predictor
38
39 of AIDS deaths than was FFI. Yet, all HR were significant for both indices. CES-D was not an
40
41 independently significant predictor of death.
42
43
44
45
46
47

48 **All deaths.** When considering all deaths, within the first 3 years after baseline measurement
49
50 (Table 5A) the VACS Index was the dominant, significant independent predictor of all deaths
51
52 (HR=2.20, 95% CI 1.83, 2.65, $\chi^2=69.04$, $p<0.0001$), followed by FFI (HR=2.06, 95% CI 1.19,
53
54 3.57, $\chi^2=6.73$, $p=0.01$). For deaths occurring later than 3 years after baseline measures (Table
55
56
57
58
59
60

1
2
3 5B), the relative influence of the VACS Index decreased (HR=1.55, 95% CI 1.30, 1.84,
4
5 $\chi^2=23.88$, $p<0.0001$), and the FFI increased (HR=2.43, 95% CI 1.58, 3.75, $\chi^2=16.18$, $p=0.0001$).
6
7
8

9
10 **AIDS deaths.** Within 3 years after baseline (Table 4C), VACS Index was the only statistically
11
12 significant independent predictor (HR=3.33, 95% CI 2.56, 4.33, $\chi^2=80.32$, $p<0.0001$) of AIDS
13
14 deaths; for AIDS death after 3 years (Table 4D), both VACS Index (HR=1.75, 95% CI 1.31,
15
16 2.35, $\chi^2=13.97$ $p=0.0002$) and FFI (HR=3.38, 95% CI 1.55, 7.37, $\chi^2=9.40$, $p=0.002$) were
17
18 independently significant.
19
20
21

22
23
24 **Non-AIDS deaths.** FFI was the most significant predictor of non-AIDS death both within (Table
25
26 5E) (HR=3.37, 95% CI 1.53, 7.40, $\chi^2=9.15$, $p=0.003$), and later (Table 5F) than 3 years post
27
28 baseline (HR=3.20, 95% CI 1.66, 6.20, $\chi^2=11.95$, $p=0.0005$). The VACS Index predicted death
29
30 later than 3 years (HR=1.41, 95% CI 1.07, 1.86, $\chi^2=5.84$, $p=0.016$), but was not quite as robust
31
32 as the FFI.
33
34
35

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CES-D score was not an independently significant (at $P < 0.05$) predictor in any AIDS or non-
AIDS death model after adjusting for FFI and VACS Index. Also of note, inclusion of ART-
naïve participants ($n=54$, for a total N of 1439), the use of modified VACS and CES-D Indices or
including an interaction term for FFI x CES-D as described in the Methods Section in the
regression model, did not change our findings.

DISCUSSION

We systematically evaluated the ability of three common indices representing physical,
biological and mental health status to predict mortality in women with HIV infection. These

1
2
3 indices - VACS, a biological HIV index; the FFI, a physical index; and the CES-D, a mental
4
5 health index - were evaluated concurrently in association with mortality over approximately 8
6
7 years (and repeated for 0-3 and >3 - ~8 years) among women with HIV infection. Overall, based
8
9 on comparative χ^2 and C-statistics, the VACS Index was the strongest predictor of death,
10
11 particularly of AIDS-related deaths and early deaths within 3 years after index assessments. The
12
13 FFI was additively informative, a better predictor of non-AIDS deaths than the VACS and a
14
15 relatively more important predictor of deaths from 3 - ~ 8 years after index assessments.
16
17
18
19
20
21

22 First published in 2003, the FFI has been a useful construct by which to predict poor quality of
23
24 life, cognitive impairment, dementia and death.¹⁸ Ten years later, the first report on a validated
25
26 VACS index specific for those with HIV infection was published.⁵ The VACS Index has, since
27
28 then, been used to predict mortality in infected and uninfected populations and has been
29
30 associated with the FFI.⁶ In the WIHS, the VACS Index and CES-D score considered together
31
32 have been independently reported to predict mortality over a 5 year period.⁴ Here we show that
33
34 with addition of the FFI, these relationships change.
35
36
37
38
39
40

41 The FFI predicts death, particularly among elderly (65 years and older).¹⁰ More recently the FFI
42
43 has been measured in younger adult populations who may be at risk for premature or earlier
44
45 aging, such as those with HIV infection.^{6,19} These studies have shown that adults with HIV
46
47 infection, even in mid-life, experience a prevalence of frailty equivalent to, and greater than, that
48
49 observed in more elderly adults.^{4,9} The reason for this early manifestation of the frailty
50
51 phenotype may be a consequence of HIV infection itself, including suboptimal medication and
52
53 control of infection early on, comorbid diseases (infectious or non-infectious)^{4,20} and/or other
54
55
56
57
58
59
60

1
2
3 lifestyle habits that may be common among those with HIV infection, such as smoking and
4
5 substance use.¹¹ While interesting, FFI fluctuations cannot be addressed in these analyses, but
6
7 will be in the future with the re-initiation of FFI assessments in the WIHS in Fall 2015. As the
8
9 FFI is a marker of the slower process of physical aging, it may continue to be more strongly
10
11 associated with non-AIDS and later deaths as was seen in this analysis.
12
13

14
15
16
17 The CES-D was significantly associated with death in models that did not adjust for VACS and
18
19 FFI (HR=2.07, 95% CI 1.55, 2.7, $p<0.0001$, $\chi^2=24.0$ in Table 2), however it was not associated
20
21 with death once VACS and FFI indices were included in the same model. Several studies that do
22
23 not consider FFI and/or VACS, including those from the WIHS, have found CES-D to be a
24
25 significant “independent” predictor of mortality.^{4,15,21-24} This study calls into question whether
26
27 CES-D is a surrogate for other vulnerabilities rather than being independently and causally
28
29 associated with death. Other studies or analyses of CES-D in relation to death tend to not include
30
31 other health indices in their models or only include VACS.⁴ It should be noted that modifying the
32
33 CES-D to exclude two items potentially overlapping with the FFI (low physical activity and
34
35 exhaustion) did not change the failure of CES-D to be significant in the multivariate models
36
37 (data not shown). Evaluating vulnerabilities in middle-aged HIV-infected women (the average
38
39 age of infected women today) is important to understanding the impact of HIV infection on
40
41 mortality over the life course. This approach has been shown for other diseases of later-life.²⁵
42
43
44
45
46
47
48 Midlife physical, biological and/or mental indicators against the background of HIV infection
49
50 may be associated with earlier death.
51
52
53
54
55
56
57
58
59
60

1
2
3 Why are multi-dimensional health indices associated with mortality in adults with HIV
4
5 infection? Throughout adult life, HIV infection is synergistic with adverse aging influences on
6
7 the immune, vascular, reproductive, and central nervous systems, thereby intensifying the aging
8
9 process.^{26,27} In our previous cross-sectional analysis of the FFI, we showed that the FFI is
10
11 associated with infectious, demographic, chronic disease, and biological factors, including
12
13 individual components of the VACS Index,⁴ lending support to this observation.
14
15
16
17
18
19

20 We chose to assess deaths occurring within 3 years versus those occurring ≥ 3 years after the
21
22 indices were measured. Studies in uninfected populations have shown that deaths occurring
23
24 within a short period of time (e.g., 3 years) tend to be those due to more rapid biological triggers
25
26 of death such as infections (e.g., HIV, pneumonia) or other acute illnesses, while longer term
27
28 deaths reflect delayed consequences of deteriorating biological and physical health.²⁸ Non-AIDS
29
30 deaths were predicted by FFI, whether those deaths occurred within versus later than 3 years.
31
32 VACS was more significant for AIDS deaths and deaths occurring within 3 years. Notably, both
33
34 VACS and FFI were stronger predictors of death (all, AIDS, non-AIDS) than age and other
35
36 variables considered in the multivariable models reflecting that these indices, more than age,
37
38 carried the consequences of deteriorating biological and physical health.
39
40
41
42
43
44
45

46 Some limitations of our approach may be that the VACS Index was specifically designed and
47
48 statistically weighted to predict mortality in HIV infected persons, and that the FFI was designed
49
50 to be descriptive of a clinically recognizable phenotype. Therefore the VACS Index may be
51
52 expected to have more explanatory power in multivariate analyses of survival. Furthermore,
53
54 there exist other frailty measures than FFI that also predict mortality.^{29,30} However, the VACS,
55
56
57
58
59
60

1
2
3 FFI and CES-D health indices were selected because they are typically reported in the literature
4 as being predictive of death in HIV+ samples. The point of our analyses was not to identify the
5 best mortality index *de novo*, but rather to systematically compare the three health indices that
6 have been reported in the literature. An additional limitation of these health indices, particularly
7 the FFI, is the blatant lack of standardization across studies. Our goal in these analyses, as
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FFI and CES-D health indices were selected because they are typically reported in the literature as being predictive of death in HIV+ samples. The point of our analyses was not to identify the best mortality index *de novo*, but rather to systematically compare the three health indices that have been reported in the literature. An additional limitation of these health indices, particularly the FFI, is the blatant lack of standardization across studies. Our goal in these analyses, as aforementioned, was to harmonize the WIHS FFI with that of another large HIV cohort study in the US - the Male Aging Cohort Study (MACS). This will facilitate our future of working together and comparing the natural history of frailty among those with HIV infection by sex and gender. Finally, the WIHS is a prospective cohort study of women (and for these analyses, HIV+ women on ART), with a defined demographic profile (See Table 1). This limits generalizability to other groups with and without HIV infection.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Aging with HIV infection is associated with geriatric morbidities or syndromes, including frailty and other health indices denoting vulnerability,³¹ however these aging morbidities often occur earlier among those with HIV infection compared to uninfected individuals.³²⁻³⁴ The question is whether HIV infection leads to more severe aging phenotypes, or accelerates their onset leading to earlier age of death.³⁵ These analyses show that two health indices, the VACS (biological) index and the FFI (physical), independently predict mortality in middle-aged women with HIV infection; in particular VACS predicted AIDS death while FFI predicted non-AIDS death. Inclusion of CES-D, a depressive symptom scale, was not independently informative once both the biological and physical health indices were considered. This is the first published report on the simultaneous evaluation of these important indices in association with mortality in women with HIV infection. These analyses point to the importance of designing interventions to address

1
2
3 components of multifaceted indices in the hopes of extending the lifespan of patients living with
4
5 chronic HIV.
6
7
8
9

10 **Author Contributions**

11 All authors contributed to this work. Hypothesis generation and manuscript drafting was led by
12
13 DG and DH; statistical analyses and interpretation was led by DH and QS; participant
14
15 recruitment and retention were accomplished by the WIHS Principal Investigators, DG, HM,
16
17 MC, MP, AS, SG, MG, and JM and project staff, SH. Manuscript editing was performed by all.
18
19
20
21
22
23

24 **Funding Statement**

25
26 Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS)
27
28 Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx
29
30 Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff, Deborah Gustafson);
31
32 Washington DC, Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium
33
34 of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium
35
36 (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen
37
38 Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-
39
40 AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-
41
42 42590) and by the *Eunice Kennedy Shriver* National Institute of Child Health and Human
43
44 Development (UO1-HD-32632). The study is co- funded by the National Cancer Institute, the
45
46 National Institute on Drug Abuse, and the National Institute on Deafness and Other
47
48 Communication Disorders. Funding is also provided by the National Center for Research
49
50 Resources (UCSF-CTSI Grant Number UL1 RR024131). Data collection was supported by a
51
52
53
54
55
56
57
58
59
60

1
2
3 dissertation grant through the National Institute of Drug Abuse (1R36DA021104-01). In
4
5 addition, Dr. Gustafson received support from NIH/NIAID ARRA Supplement No. 54492,
6
7
8 Swedish Research Council for Health, Working Life and Welfare (AGECAP 2013-2300) and the
9
10 SUNY Research Foundation.
11

12
13
14
15 The contents of this publication are solely the responsibility of the authors and do not necessarily
16
17 represent the official views of the National Institutes of Health.
18
19

20
21
22 We thank the women participating in WIHS for their time, cooperation, and support.
23

24 **Competing Interest**

25
26 There are no competing interests to declare.
27
28
29

30 **STROBE Criteria**

31
32 This manuscript meets the STROBE criteria for longitudinal cohort studies.
33
34
35
36
37

38 **Data Sharing**

39
40 Technical appendix, statistical code, and dataset are available from the WIHS Statistical Analysis
41
42 Center, WD-MAC.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Kirk JB, Goetz MB. Human immunodeficiency virus in an aging population, a complication of success. *Journal of the American Geriatrics Society* 2009; **57**(11): 2129-38.
2. Vance DE, McGuinness T, Musgrove K, Orel NA, Fazeli PL. Successful aging and the epidemiology of HIV. *Clin Interv Aging* 2011; **6**: 181-92.
3. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. *PloS one* 2013; **8**(12): e81355.
4. Cohen MH, Hotton AL, Hershov RC, et al. Gender-related risk factors improve mortality predictive ability of VACS Index among HIV-infected women. *J Acquir Immune Defic Syndr* 2015.
5. Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. *J Acquir Immune Defic Syndr* 2013; **62**(2): 149-63.
6. Escota GV, Patel P, Brooks JT, et al. Short communication: The Veterans Aging Cohort Study Index is an effective tool to assess baseline frailty status in a contemporary cohort of HIV-infected persons. *AIDS research and human retroviruses* 2015; **31**(3): 313-7.
7. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *The journals of gerontology Series A, Biological sciences and medical sciences* 2001; **56**(3): M146-56.
8. Rizzoli R, Reginster JY, Arnal JF, et al. Quality of life in sarcopenia and frailty. *Calcif Tissue Int* 2013; **93**(2): 101-20.
9. Terzian AS, Holman S, Nathwani N, et al. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. *J Womens Health (Larchmt)* 2009; **18**(12): 1965-74.
10. Shamliyan T, Talley KM, Ramakrishnan R, Kane RL. Association of frailty with survival: a systematic literature review. *Ageing Res Rev* 2013; **12**(2): 719-36.
11. Piggott DA, Muzaale AD, Mehta SH, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. *PloS One* 2013; **8**(1): e54910.
12. Ravindrarajah R, Lee DM, Pye SR, et al. The ability of three different models of frailty to predict all-cause mortality: Results from the European Male Aging Study (EMAS). *Archives of gerontology and geriatrics* 2013; **57**(3): 360-8.
13. Andrew MK, Fisk JD, Rockwood K. Psychological well-being in relation to frailty: a frailty identity crisis? *International Psychogeriatr Assoc* 2012; **24**(8): 1347-53.
14. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. *Clin Diagn Lab Immunol* 2005; **12**(9): 1013-9.
15. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. *The American journal of medicine* 2002; **113**(2): 91-8.
16. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; **150**(9): 604-12.
17. Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. *Psychol Aging* 1997; **12**(2): 277-87.
18. Hirsch C, Anderson ML, Newman A, et al. The association of race with frailty: the cardiovascular health study. *Annals of epidemiology* 2006; **16**(7): 545-53.

19. Erlandson KM, Schrack JA, Jankowski CM, Brown TT, Campbell TB. Functional impairment, disability, and frailty in adults aging with HIV-infection. *Curr HIV/AIDS Rep* 2014; **11**(3): 279-90.
20. Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. *Infection* 2004; **32**(1): 33-46.
21. Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. *Am J Public Health* 2004; **94**(7): 1133-40.
22. Coughlin SS. Invited commentary: Prevailing over acquired immune deficiency syndrome and depressive symptoms. *American journal of epidemiology* 2013; **177**(2): 126-8; discussion 9-30.
23. Farinpour R, Miller EN, Satz P, et al. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). *J Clin Exp Neuropsychol* 2003; **25**(5): 654-70.
24. Lyketsos CG, Hoover DR, Guccione M, et al. Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study. *JAMA* 1993; **270**(21): 2563-7.
25. Ritchie K, Ritchie CW, Yaffe K, Skoog I, Scarmeas N. Is late-onset Alzheimer's disease really a disease of midlife? *Translational Res Clin Interventions* 2015; **1**: 122-30.
26. Nguyen N, Holodniy M. HIV infection in the elderly. *Clin Interv Aging* 2008; **3**(3): 453-72.
27. Kalayjian RC, Landay A, Pollard RB, et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. *J Infect Dis* 2003; **187**(12): 1924-33.
28. Gustafson DR, Mazucco S, Ongaro F, et al. Body mass index, cognition, disability, APOE genotype, and mortality: the "Treviso Longeva" Study. *Am J Geriatr Psychiatry* 2012; **20**(7): 594-602.
29. Kulminski AM, Ukraintseva SV, Kulminskaya IV, Arbeev KG, Land K, Yashin AI. Cumulative deficits better characterize susceptibility to death in elderly people than phenotypic frailty: lessons from the Cardiovascular Health Study. *Journal of the American Geriatrics Society* 2008; **56**(5): 898-903.
30. Theou O, Brothers TD, Mitnitski A, Rockwood K. Operationalization of frailty using eight commonly used scales and comparison of their ability to predict all-cause mortality. *Journal of the American Geriatrics Society* 2013; **61**(9): 1537-51.
31. Greene M, Covinsky KE, Valcour V, et al. Geriatric Syndromes in Older HIV-Infected Adults. *J Acquir Immune Defic Syndr* 2015; **69**(2): 161-7.
32. Desquilbet L, Jacobson LP, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. *The journals of gerontology Series A, Biological sciences and medical sciences* 2007; **62**(11): 1279-86.
33. Desquilbet L, Jacobson LP, Fried LP, et al. A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. *The journals of gerontology Series A, Biological sciences and medical sciences* 2011; **66**(9): 1030-8.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
34. Desquilbet L, Margolick JB, Fried LP, et al. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. *J Acquir Immune Defic Syndr* 2009; **50**(3): 299-306.
35. Onen NF, Overton ET. A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging. *Current aging science* 2011; **4**(1): 33-41.

For peer review only

Table 1. Baseline characteristics of HIV+ WIHS participants who are not ART-naïve

Variables	N (%) or Mean \pm SD
Indices	
Fried Frailty Index (FFI)	
0-2 points	1143 (82.5)
3-5 points	242 (17.5)
VACS Index Score (0-164 points)	28.9 \pm 19.4
CES-D score \geq 16 points	
No	844 (60.9)
Yes	541 (39.1)
Outcomes	
All Deaths	
3 Years or Less	73 (5.3)
> 3-8 years	111 (8.0)
AIDS deaths ^a	
3 Years or Less	39 (2.8)
> 3-8 years	35 (2.5)
Non-AIDS deaths ^a	
3 Years or Less	32 (2.3)
> 3-8 years	45 (3.2)
HIV variables	
CD4 count (cells/mm ³)	
\geq 500	554 (40.0)
200-499	614 (44.3)
< 200	217 (15.7)
Viral Load (copies/ml)	
< 500	820 (59.2)
500-100,000	510 (36.8)
>100,000	55 (4.0)
Hemoglobin (g/dl)	
\geq 14	209 (15.1)
12-13.9	743 (53.6)
10-11.9	362 (26.1)
<10	71 (5.1)
FIB4	
< 1.45	1018 (73.5)
1.45-3.25	280 (20.2)
> 3.25	87 (6.3)
eGFR (ml/min)	
\geq 60	1277 (92.2)
45-59.9	71 (5.1)
30-44.9	15 (1.1)
< 30	22 (1.6)
Hepatitis C Co-infection	298 (21.5)

Demographic Variables

Average age (years, mean \pm SD)	42.6 \pm 8.8
Race/Ethnicity	
White	324 (23.4)
Black	806 (58.2)
Others	255 (18.4)
Education	
< High School	536 (38.7)
\geq High School	847 (61.2)
Mission	2 (0.1)
Smoking History	
Not current smoking	786 (56.8)
Current smoking	599 (43.2)
Income	
< \$12,000	669 (48.3)
\geq \$12,000	668 (48.2)
Missing	48 (3.5)
Current Alcohol Drinking	
Abstainer/None	743 (53.6)
Low	490 (35.4)
Moderate	129 (9.3)
High	23 (1.7)
Body Mass Index (BMI), kg/m ²	
BMI < 30	916 (66.1)
BMI \geq 30 (Obesity)	461 (33.3)
Missing	8 (0.6)
Current ART use	
No	400 (28.9)
Yes (HAART)	984 (71.0)
Missing	1 (0.1)
Prior AIDS Defining Illness	
No	802 (57.9)
Yes	583 (42.1)
Injection Drug Use Ever	
Yes	305 (22.0)
No	1071 (77.3)
Missing	9 (0.6)
Prior Pneumonia	
No	1080 (78.0)
Yes	305 (22.0)
Current / Prior Hypertension	
No	964 (69.6)
Yes	421 (30.4)
History of Diabetes	

No	1195 (86.3)
Yes	190 (13.7)
Prior Cancer Diagnosis	
No	1220 (88.1)
Yes	165 (11.9)

^aFor some deaths, cause of death could not be classified as AIDS / non-AIDS, thus the number of AIDS + non-AIDS deaths does not sum to total deaths

For peer review only

Table 2. Proportional Hazards models of time to all deaths by FFI, VACS Index, CES-D, age group, and potential confounders among HIV+ women who are not ART naïve.

Variable	Crude HR (95% CI)	χ^2	P-value
Univariate Analyses of Indices			
VACS Score (0-164), per 20 points	2.20 (1.98, 2.45)	214.6	< 0.0001
FFI 3-5 vs 0-2	3.92 (2.92, 5.26)	83.2	< 0.0001
CES-D (< 16 vs \geq 16)	2.07 (1.55, 2.77)	24.0	<0.0001
Univariate Analyses of Potential Confounders			
Age per Decade	1.62 (1.38, 1.89)	36.14	<0.0001
Race/ethnicity		8.95 (2 df)	0.011
White vs black	0.55 (0.37, 0.83)	8.02	0.005
Others vs black	0.74 (0.49, 1.11)	2.15	0.140
Education \geq high school vs < high school	0.68 (0.51, 0.90)	6.96	0.008
Smoking (current vs no)	3.41 (2.49, 4.69)	57.5	<0.0001
Income (< \$12,000 vs \geq \$12,000)	2.03 (1.49, 2.77)	19.8	<0.0001
Drinking		27.25 (3 df)	<0.0001
Low vs Abstainer/None	0.59 (0.42, 0.84)	8.59	0.003
Moderate vs Abstainer/None	1.27 (0.82, 1.98)	1.14	0.290
High vs Abstainer/None	3.48 (1.76, 6.87)	12.9	0.0003
BMI, kg/m ² (\geq 30 vs <30)	0.57 (0.41, 0.81)	10.2	0.001

Table 3. Concordance statistics from Proportional hazards models for health indices used to predict death among HIV+ women who were not ART naïve.

Variables	All deaths	AIDS deaths	Non-AIDS deaths
CES-D + VACS Index + FFI + Demographics ^a	0.83	0.89	0.81
VACS Index + FFI + Demographics	0.83	0.89	0.81
VACS Index + CES- D+ Demographics	0.82	0.89	0.78
FFI + CES-D + Demographics	0.78	0.80	0.80
VACS Index + Demographics	0.81	0.89	0.77
FFI + Demographics	0.77	0.78	0.80
CES-D+ Demographics	0.75	0.77	0.75
Demographics Only*	0.74	0.74	0.76

^aDemographic variables included were: age, BMI, race/ethnicity, income, education, cigarette smoking & alcohol use.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 4. VACS Index, FFI, and CES-D individually predict time to all, AIDS and non-AIDS deaths over ~8 years follow-up among HIV+ women who are not ART naïve.

Index	All deaths			AIDS deaths			Non-AIDS deaths		
	χ^2	HR ^a (95% CI)	P-value	χ^2	HR (95% CI)	P-value	χ^2	HR (95% CI)	P-value
VACS Score (0-164), per 20 points	89.81	1.82 (1.61, 2.06)	<0.0001	94.95	2.52 (2.09, 3.04)	>0.0001	21.22	3.27 (1.97, 5.40)	<0.0001
FFI 3-5 vs 0-2	24.70	2.35 (1.68, 3.28)	<0.0001	8.44	2.27 (1.30, 3.93)	0.004	6.13	1.31 (1.06, 1.62)	0.013
CES-D (< 16 vs ≥ 16)	0.75	1.16 (0.83, 1.60)	0.38	2.04	1.49 (0.86, 2.59)	0.15	0.17	0.90 (0.55, 1.48)	0.68
Age per decade	2.03	1.15 (0.95, 1.39)	0.15	2.88	0.77 (0.56, 1.04)	0.09	7.48	1.50 (1.12, 2.01)	0.006

^aMultivariate models included race/ethnicity; education less than or equal to vs greater than high school; smoking current vs no; income less than vs greater than or equal to \$12,000 annually; drinking low, moderate or high vs none; and BMI at least than vs less 30 kg/m²

Table 5. Multivariable proportional hazards models of time to all, AIDS and non-AIDS deaths within 3 years vs greater than 3 years by VACS Index, FFI, CES-D and age among HIV+ women who are not ART naïve.

Variable	A. All Deaths Within 3 Years After FFI Visit			B. All Deaths Later Than 3 Years After FFI Visit		
	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-value	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-Value
VACS Index per 20 points	69.04	2.20 (1.83, 2.65)	<0.0001	23.88	1.55 (1.30, 1.84)	<0.0001
FFI (3-5 vs 0-2 points)	6.73	2.06 (1.19, 3.57)	0.01	16.18	2.43 (1.58, 3.75)	0.0001
CES-D (< 16 vs ≥16 points)	1.01	1.32 (0.77, 2.28)	0.31	0.11	1.07 (0.71, 1.62)	0.74
Age per Decade	0.09	1.05 (0.77, 1.42)	0.76	3.24	1.26 (0.98, 1.61)	0.07
Variable	C. AIDS Deaths Within 3 Years or Less After FFI Visit			D. AIDS Deaths Later Than 3 Years After FFI Visit		
	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-value	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-Value
VACS Index per 20 points	80.32	3.33 (2.56, 4.33)	0.0000	13.97	1.75 (1.31, 2.35)	0.0002
FFI (3-5 vs 0-2 points)	0.88	1.45 (0.67, 3.14)	0.34	9.40	3.38 (1.55, 7.37)	0.002
CES-D (< 16 vs ≥16 points)	1.96	1.73 (0.80, 3.73)	0.17	0.81	1.43 (0.65, 3.14)	0.37
Age per Decade	2.42	0.72 (0.47, 1.09)	0.12	0.09	0.93 (0.58, 1.50)	0.77

	E. Non-AIDS Deaths Within 3 Years or Less After FFI Visit			F. Non-AIDS Deaths Later Than 3 Years After FFI Visit		
	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-value	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-Value
VACS Index per 20 points	0.80	1.16 (0.83, 1.62)	0.37	5.84	1.41 (1.07, 1.86)	0.016
FFI (3-5 vs 0-2 points)	9.15	3.37 (1.53, 7.40)	0.003	11.95	3.20 (1.66, 6.20)	0.0005
CES-D (< 16 vs ≥16 points)	0.15	1.17 (0.54, 2.54)	0.70	0.60	0.77 (0.40, 1.48)	0.44
Age per Decade	7.43	1.90 (1.20, 3.02)	0.006	1.44	1.26 (0.86, 1.84)	0.23

^aMultivariate models included race/ethnicity; education less than or equal to vs greater than high school; smoking current vs no; income less than vs greater than or equal to \$12,000 annually; drinking low, moderate or high vs none; and BMI at least than vs less 30 kg/m²




Figure 1. WIHS participants with the VACS Index, FFI, and CES-D measured in 2005 and follow-up over approximately 8 years.

245x183mm (96 x 96 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies
All items in the STROBE checklist are accomplished, see page numbers by items listed below.

	Item No & Page#	Recommendation
Title and abstract	1, P1	(a) Indicate the study's design with a commonly used term in the title or the abstract
	P3	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2, P5-6	Explain the scientific background and rationale for the investigation being reported
Objectives	3, P6	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4, P6	Present key elements of study design early in the paper
Setting	5, P6-9	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6, P6-7	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7, P7-9	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*, P7-9	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias, NA
Study size	10, P7	Explain how the study size was arrived at
Quantitative variables	11, P9-10	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12 P9-10 P9-10	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed, NA
	P10	(d) <i>Cohort study</i> —If applicable, explain loss to follow-up was addressed, NA <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed, NA <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy, NA
		(e) Describe any sensitivity analyses

Continued on next page

Results

Participants	13*,	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
	P31	(b) Give reasons for non-participation at each stage, NA
	P31	(c) Consider use of a flow diagram
Descriptive data	14*,	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
	P23-25	(b) Indicate number of participants with missing data for each variable of interest, NA
	P31	(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*, P7-	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time
	9, P31	<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure, NA
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures, NA
Main results	16, P10-	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
	13	(b) Report category boundaries when continuous variables were categorized
	P8-9	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period, NA
Other analyses	17, P11	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18, P12-13	Summarise key results with reference to study objectives
Limitations	19, P15-16	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20, P12-17	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21, P4, P12-17	Discuss the generalisability (external validity) of the study results

Other information

Funding	22, P17-18	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	------------	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Predicting death over 8 years in a prospective cohort of HIV-infected women. The Women's Interagency HIV Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013993.R2
Article Type:	Research
Date Submitted by the Author:	27-Mar-2017
Complete List of Authors:	Gustafson, Deborah R.; Suny Downstate Med Ctr, Neurology Shi, Qiuhu; New York Medical College School of Health Sciences and Practice, Epidemiology and Community Health Holman, Susan; SUNY Downstate Medical Center College of Medicine, Medicine Minkoff, Howard; Maimonides Medical Center, Cohen, Mardge; Rush University, Medicine Plankey, PhD, Michael; Georgetown University, Infectious Disease Epidemiology Havlik, MD, MPH, Richard; Arrow Health, Internal Medicine Sharma, Anjali; Yeshiva University Albert Einstein College of Medicine, Epidemiology Infectious Disease Gange, Stephen ; Johns Hopkins University Bloomberg School of Public Health, Epidemiology Gandhi, Monica; University of California San Francisco School of Medicine, Infectious Disease Milam, Joel; Keck School of Medicine of the University of Southern California, Preventive Medicine Hoover, Donald; The State University of New Jersey, Department of Statistics
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Epidemiology, Infectious diseases, Geriatric medicine, Mental health
Keywords:	Frailty, HIV, HCV, Aging

SCHOLARONE™
Manuscripts

1
2
3 **Predicting death over 8 years in a prospective cohort of HIV-infected women. The**
4
5 **Women's Interagency HIV Study**
6
7
8
9

10 Deborah R. Gustafson, MS, PhD^a; Qiuhu Shi, PhD^b; Susan Holman, RN, MS^c; Howard Minkoff,
11 MD^{d,e}; Mardge H. Cohen, MD^f; Michael W. Plankey, PhD^g; Richard Havlik, MD, MPH^{h,i}; Anjali
12 Sharma, MD, MS^j; Stephen Gange, PhD^k; Monica Gandhi, MD^l; Joel Milam PhD^m; Donald R.
13 Hoover MPH, PhDⁿ
14
15
16
17
18
19

20
21
22 ^aDepartment of Neurology, State University of New York - Downstate Medical Center,
23 Brooklyn, NY; ^bSchool of Health Sciences and Practice, New York Medical College, Valhalla,
24 NY; ^cDepartment of Medicine, State University of New York - Downstate Medical Center;
25
26
27
28
29 ^dMaimonides Medical Center, Brooklyn, NY; ^eDepartment of Obstetrics and Gynecology, State
30 University of New York - Downstate Medical Center, Brooklyn, NY; ^fDepartments of Medicine,
31 Stroger Hospital of Cook County Health and Hospital System and Rush University; ^gDepartment
32 of Medicine, Division of Infectious Diseases, Georgetown University Medical Center; ^hAIDS
33 Community Research in American, New York, NY; ⁱArrow Health, Bethesda MD; ^jDepartment
34 of Medicine, Albert Einstein College of Medicine, Bronx, NY; ^kDepartment of Epidemiology,
35 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; ^lDepartment of Medicine,
36 University of California, San Francisco (UCSF); ^mDepartment of Preventive Medicine,
37 University of Southern California; ⁿStatistics and Biostatistics & Institute for Health, Health
38 Care Policy and Aging Research Rutgers the State University of New Jersey.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 Deborah R. Gustafson, PhD, MS (corresponding author)
56
57
58
59
60

1
2
3 Professor, Department of Neurology

4
5
6 SUNY Downstate Medical Center

7
8 450 Clarkson Ave, MSC 1213

9
10 Brooklyn, NY 11203

11
12 deborah.gustafson@downstate.edu

13
14
15 718-270-1581

16
17
18
19
20 Running head: Frailty in HIV+/HIV- women

21
22 **Key Words:** Frailty, HIV, HCV, Aging

23
24
25
26
27 DISCLOSURE STATEMENT: The authors have nothing to disclose.

28
29 Abstract Word Count: 218/250 allowed

30
31 Text Word Count: 3380

32
33 1 Figure, 5 tables

34
35
36 References: 37

ABSTRACT

Objectives. Predicting mortality in middle-aged HIV-infected (HIV+) women on antiretroviral therapies (ART) is important for understanding the impact of HIV infection. Several health indices have been used to predict mortality in women with HIV infection. We evaluated: 1) an HIV biological index, Veterans Aging Cohort Study (VACS); 2) a physical index, Fried Frailty Index (FFI); and 3) a mental health index, Centers for Epidemiologic Studies-Depression (CES-D). Proportional hazards regression analyses were used to predict death and included relevant covariates.

Design. Prospective, observational cohort

Setting. Multicenter, across 6 sites in the United States

Participants. 1385 multirace/ethnic HIV+ women on ART in 2005

Primary and secondary outcomes. All deaths, AIDS-deaths and non-AIDS deaths up to ~8 years from baseline

Results. Included together in one model, VACS Index was the dominant, significant independent predictor of all deaths within 3 years (HR=2.20, 95% CI 1.83, 2.65, $\chi^2=69.04$, $p<0.0001$), and later than 3 years (HR=1.55, 95% CI 1.30, 1.84 $X^2=23.88$, $p<0.0001$); followed by FFI within 3 years (HR=2.06, 95% CI 1.19, 3.57, $\chi^2=6.73$, $p=0.01$) and later than 3 years (HR=2.43, 95% CI 1.58, 3.75, $X^2=16.18$, $p=0.0001$). CES-D score was not associated with mortality.

Conclusions and Relevance. This is the first simultaneous evaluation of three common health indices in HIV infected adults. Indices reflecting physical and biological aging were associated with death.

Article summary

Strengths and limitations of this study

- Longitudinal cohort study with follow-up of almost 10 years
- Well-phenotyped White, African American and Latina HIV+ women
- Reputable standardized and validated physical, biological and emotional health indices
- Somewhat limited generalizability since a survivor sample of urban women with strong, consistent research study-related HIV care and social support
- Health indices and mortality were examined at mid-life, a period when risk of death is low.

INTRODUCTION

HIV infection continues as a major global health issue affecting approximately 36 million people worldwide. HIV infection has evolved from a fatal infection to a treatable, chronic condition of aging,^{1,2} accompanied by multiple morbidities and rising healthcare costs. The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), observed that life expectancy of HIV infected (HIV+) adults increased from 36 to 51 years between 2000 and 2007,³ primarily due to treatment advances. In 2015, over half of HIV+ Americans are ≥ 50 years old.³ Therefore, HIV infection may prove to represent a modern-day phenomenon of achieving healthy old age accompanied by improved longevity.

Predicting death in chronic HIV infection may assist in the design of interventions to understand, prevent, cure or minimize age-related impairments, improve health and increase lifespan. Several health indices predict death in adults with HIV infection - the Veterans Aging Cohort Study (VACS) Index; Fried Frailty Index (FFI); and the Centers for Epidemiologic Studies – Depression (CES-D) score. These indices represent biological, physical and mental health vulnerabilities that worsen with age. The only HIV-specific mortality index is the VACS Index, which has been reproduced in North American and European patient populations including Highly Active ART (HAART) users in the Women's Interagency HIV Study (WIHS).^{4,5} The VACS Index creates a clinical HIV mortality risk score by summing pre-assigned points for age, routinely monitored indicators of HIV disease and general indicators of organ system function.^{5,6} The FFI is most commonly used when describing aging in both general and HIV+ populations.^{7,8} Frailty is a common co-morbidity of HIV infection, observed even during middle age.^{4,9} The FFI includes measures of gait speed, handgrip strength, body weight loss, physical activity, and exhaustion and predicts death.¹⁰⁻¹² The Centers for Epidemiologic Studies – Depression (CES-D)

1
2
3 score measures mental health¹³ and has been independently associated with mortality,
4 particularly among women with HIV infection on HAART in the WIHS.⁴
5
6
7
8
9

10 The objective of our analyses was to evaluate, among HIV+ women, the association of the
11 aforementioned, frequently used health indices: VACS, FFI, and CES-D, with death (both AIDS-
12 and non-AIDS related). All indices were measured in mid-life (average age 39 years) in our
13 analyses and evaluated for prediction of mortality for up to ~8 years. This follow-up period was
14 further broken down into short-term (within 0-3 years) and long-term (>3- ~8 years) deaths,
15 since studies show that prediction of death may vary depending on the exposure being evaluated
16 in relation to more immediate precipitating diseases or conditions versus chronic outcomes.
17
18
19
20
21
22
23
24
25
26
27
28

29 **METHODS**

30
31 **Study Population.** WIHS is a prospective, observational cohort suitable to study the intersection
32 of HIV-infection and aging. WIHS participants enrolled at six sites (Bronx/Manhattan, Brooklyn,
33 Chicago, Los Angeles, San Francisco and Washington DC); methods, and baseline cohort
34 characteristics have been described previously.¹⁴ Participants have visits every 6 months, which
35 include an extensive face-to-face interview by trained interviewers, medical examinations, and
36 laboratory specimen collection. Written informed consent was provided by all WIHS participants
37 via human subjects protocols that were approved by institutional review committees at each
38 affiliated institution (Albert Einstein College of Medicine and Montefiore Medical Center
39 Institutional Review Board, #03-07-174; Cook County Bureau of Health Services Institutional
40 Review Board, #15-084; Georgetown University Institutional Review Board Protocol #1993-
41 077; State University of New York - Downstate Medical Center Institutional Review Board,
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 #266921; University of California San Francisco Committee on Human Research, #1003720;
4
5 and University of Southern California Institutional Review Board HS-944027.)
6
7
8
9

10 Of the HIV+ women actively enrolled in 2005, 1395 completed an assessment of the FFI. Of
11 these, 1385 women reported current use of antiretroviral therapy and had measures of both
12
13 VACS index and CES-D and are included in the current analyses.
14
15
16
17
18
19

20 **Inclusion criteria.** Women included in these analyses are members of the WIHS cohort and had
21
22 to have adequately completed all indices (VACS, FFI, CES-D) in 2005 for evaluation in
23
24 association with mortality.
25
26
27
28

29 **Primary outcome.** Mortality over the ~8 years, 2005-2013 (also subcategorized into 0-3 and >3
30
31 - ~8 years) subsequent to measurement of the aging vulnerability indices, was the primary
32
33 outcome. The US National Death Index identified numbers and causes of death from Jan 1, 2005
34
35 through Dec 31, 2013. Causes of death were subdivided into AIDS and non-AIDS deaths based
36
37 on consensus opinion from a panel of WIHS investigators.¹⁵ (See Figure 1) AIDS deaths
38
39 included: pneumonia, PML, PCP, wasting syndrome, CNS lymphoma, candida, CMV,
40
41 Cryptococcus, toxoplasmosis, TB/mycobacterium, cervical cancer, pulmonary hypertension,
42
43 dementia/neurologic, renal failure, multi-organ failure and pancreatitis. Non-AIDS deaths
44
45 included: non-AIDS related malignancy, gastrointestinal, trauma, drug/alcohol overdose, heart
46
47 disease, lung disease, liver disease, kidney disease, neurologic/stroke, hemorrhage, pneumonia,
48
49 psychiatric, surgical complication, or pregnancy complication. For some, cause of death could
50
51
52
53
54
55
56
57
58
59
60

1
2
3 not be classified as AIDS or non-AIDS, thus the sum of these two subcategories is less than the
4 total number of deaths during the follow-up period.
5
6
7
8
9

10 **Primary Predictors of Death.** There were three primary predictors of interest: VACS score,
11 FFI, and CES-D score. The VACS Index facilitates a mortality risk score created by summing
12 pre-assigned points for age, routinely monitored indicators of HIV disease (CD4 count and HIV-
13 1 RNA), and viral hepatitis C infection (HCV); and general indicators of organ system injury
14 including hemoglobin, FIB-4, and estimated glomerular filtration rate, eGFR (ml/min). We
15 calculated eGFR based on the CKD-EPI equation.¹⁶ The VACS Index has a maximum score of
16 164.
17
18
19
20
21
22
23
24
25
26
27
28

29 The FFI was defined using well-described criteria.⁷ A woman was classified as frail if she
30 exhibited three or more of five characteristics: 1) impaired mobility, 2) reduced grip strength, 3)
31 physical exhaustion, 4) unintentional weight loss and 5) low physical activity. At each site,
32 mobility was measured using a 3-4 meter timed gait test, and impaired mobility was defined as
33 the lowest quintile of performance among HIV negatives. Similarly, grip strength was measured
34 using a dominant hand-held dynamometer with maximum force; reduced grip strength was the
35 lowest quintile of performance among HIV negatives. Physical exhaustion was a “Yes” to the
36 question: “During the past four weeks, as a result of your physical health, have you had difficulty
37 performing your work or other activities (for example, it took extra efforts)?” Low physical
38 activity was a “Yes” to “Does your health now limit you in vigorous activities, such as running,
39 lifting heavy objects, or participating in strenuous sports?” Unintentional weight loss was a
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 “Yes” to: “Since your last visit, have you had unintentional weight loss of at least 10 pounds?”
4
5

6 If at least 3 components were available, the total out of 3 (or 4) was calculated.
7
8
9

10 The 20-item CES-D, is a depressive symptom screening tool comprised of 20 items and totaling
11
12 60 points. A cut point of 16 was used to denote a symptom burden of clinical relevance.¹⁷
13
14

15
16
17 **Statistical analyses.** We used single variable and multivariable proportional hazards models to
18
19 address the questions of which indices (of FFI, VACS or CES-D), when measured at mid-life in
20
21 this sample of HIV+ women, best predicted AIDS, non-AIDS and all death. Concordance
22
23 statistics (C-statistics) were also calculated. The C-statistic for time to event outcomes is
24
25 equivalent to the area under the Receiver Operating Characteristic (ROC) curve for standard
26
27 binomial outcomes (range 0.5-1.0). It describes the probability of death associated with a higher
28
29 health index score or combination of higher health index scores in a randomly selected
30
31 participant compared to those who do not die.¹⁸ Besides FFI, VACS and CES-D, tested
32
33 covariates were those found to be significant in cross-sectional analyses.⁴ These covariates
34
35 included race/ethnicity, education, smoking, annual income, alcohol drinking, intravenous drug
36
37 use (IDU) history, body mass index (BMI), prior AIDS defining illness, pneumonia, cancer,
38
39 diabetes and hypertension. Methods for determining HIV and HCV infection status, Acquired
40
41 Immunodeficiency Syndrome (AIDS) diagnosis, CD4 cell count, HIV viral load, ART use, and
42
43 IDU were described previously.⁹ In addition, in relation to the health indices, we refit models i)
44
45 restricting follow up time to the first 3 years after measurement (i.e. censoring at 3 years), and ii)
46
47 starting follow up time at 3 years after the health indices measurements (i.e. truncating prior to 3
48
49 years). In addition, the interaction between FFI and CES-D was considered. Results of
50
51
52
53
54
55
56
57
58
59
60

1
2
3 proportional hazards regression models are presented as Hazards Ratios (HR) with 95%
4
5 Confidence Intervals (CI). The χ^2 statistic is also presented to facilitate comparison of strength of
6
7 association between models since the HR scale of each aging vulnerability index is not the same.
8
9
10 Data analyses were accomplished using SAS 9.4. C-statistics were calculated using STATA
11
12 Version 12.1.
13

14
15
16
17 *Modified VACS and CES-D Indices.* While not reported here, as a sensitivity analysis, we reran
18
19 the statistical models using a modified VACS Index and a modified CES-D. Our modified
20
21 VACS Index did not include VACS age groups in the derivation of total points due to the
22
23 younger age of our sample (VACS Index lowest age group is <50 years). Thus, a maximum
24
25 score of 136 was attainable. We then adjusted for age as age decades that reflected our sample as
26
27 a separate covariate in multivariate analyses. Our modified CES-D score resulted from
28
29 excluding two CES-D symptoms that overlap with the FFI. The excluded CES-D symptoms were
30
31 ‘this past week I could not get going’ (overlaps with low physical activity in the FFI) and ‘this
32
33 past week everything was an effort’ (overlaps with exhaustion in the FFI).
34
35
36
37
38
39
40

41 RESULTS

42
43 Data were available for all indices on 1385 HIV+ women (average age 42.6 ± 8.8 years) who
44
45 reported ART use. The average VACS score was 28.9 ± 19.4 (possible range 0-164); prevalence
46
47 of frailty (defined as FFI = 3-5) was 17.5%; and 39.1% had a CES-D score of at least 16 points
48
49 indicating a clinically relevant depressive symptom burden. With regard to calculating the FFI,
50
51 of 1385 women, 1166 (84.2%) had no missing components, 94 (6.8%) had one missing
52
53 component and 125 (9.0%) had 2 missing components. The three indices, as well as individual
54
55
56
57
58
59
60

VACS components, demographic/health behavior, infectious disease, chronic aging-related disease variables, number and types of deaths are presented in Table 1. The crude HR (95% CI) for all deaths by aging vulnerability indices and demographic/health behavior, infectious disease and chronic aging-related disease variables are presented in Table 2.

C-Statistics. When evaluated in multivariable models, worse (higher) FFI, VACS, and CES-D scores were each significantly associated with a more rapid onset of mortality, additive to higher age and several other covariates (Table 3). As a single index added on to demographics, the VACS performed best for all and AIDS deaths, however the FFI was best for non-AIDS deaths. The C-statistics were qualitatively higher for AIDS death reaching 0.89 with demographics and VACS in the model and remaining at 0.89 in the full model than for non-AIDS death which reached 0.80 with VACS and FFI in the model and only improving to 0.81 in the full model.

Using multivariable models that included all indices, we separately evaluated all deaths up to ~8 years from baseline (Table 4) and subdivided by timing of death (short-term, 0 - 3 years vs long-term, >3 to ~8 years from baseline, Table 5). We also modeled AIDS and non-AIDS deaths separately over the same time periods. Over the entire follow-up period, FFI was a stronger predictor of non-AIDS deaths than was the VACS Index, while VACS was a stronger predictor of AIDS deaths than was FFI. Yet, all HR were significant for both indices. CES-D was not an independently significant predictor of death.

All deaths. When considering all deaths, within the first 3 years after baseline measurement (Table 5A) the VACS Index was the dominant, significant independent predictor of all deaths

(HR=2.20, 95% CI 1.83, 2.65, $\chi^2=69.04$, $p<0.0001$), followed by FFI (HR=2.06, 95% CI 1.19, 3.57, $\chi^2=6.73$, $p=0.01$). For deaths occurring later than 3 years after baseline measures (Table 5B), the relative influence of the VACS Index decreased (HR=1.55, 95% CI 1.30, 1.84, $\chi^2=23.88$, $p<0.0001$), and the FFI increased (HR=2.43, 95% CI 1.58, 3.75, $\chi^2=16.18$, $p=0.0001$).

AIDS deaths. Within 3 years after baseline (Table 5C), VACS Index was the only statistically significant independent predictor (HR=3.33, 95% CI 2.56, 4.33, $\chi^2=80.32$, $p<0.0001$) of AIDS deaths; for AIDS death after 3 years (Table 5D), both VACS Index (HR=1.75, 95% CI 1.31, 2.35, $\chi^2=13.97$, $p=0.0002$) and FFI (HR=3.38, 95% CI 1.55, 7.37, $\chi^2=9.40$, $p=0.002$) were independently significant.

Non-AIDS deaths. FFI was the most significant predictor of non-AIDS death both within (Table 5E) (HR=3.37, 95% CI 1.53, 7.40, $\chi^2=9.15$, $p=0.003$), and later (Table 5F) than 3 years post baseline (HR=3.20, 95% CI 1.66, 6.20, $\chi^2=11.95$, $p=0.0005$). The VACS Index predicted death later than 3 years (HR=1.41, 95% CI 1.07, 1.86, $\chi^2=5.84$, $p=0.016$), but was not quite as robust as the FFI.

CES-D score was not an independently significant (at $P < 0.05$) predictor in any AIDS or non-AIDS death model after adjusting for FFI and VACS Index. Also of note, inclusion of ART-naïve participants ($n=54$, for a total N of 1439), the use of modified VACS and CES-D Indices or including an interaction term for FFI x CES-D as described in the Methods Section in the regression model, did not change our findings.

DISCUSSION

We systematically evaluated the ability of three common indices representing physical, biological and mental health status to predict mortality in women with HIV infection. These indices - VACS, a biological HIV index; the FFI, a physical index; and the CES-D, a mental health index - were evaluated concurrently in association with mortality over approximately 8 years (and repeated for 0-3 and >3 - ~8 years) among women with HIV infection. Overall, based on comparative χ^2 and C-statistics, the VACS Index was the strongest predictor of death, particularly of AIDS-related deaths and early deaths within 3 years after index assessments. The FFI was additively informative, a better predictor of non-AIDS deaths than the VACS and a relatively more important predictor of deaths from 3 - ~ 8 years after index assessments.

First published in 2003, the FFI has been a useful construct by which to predict poor quality of life, cognitive impairment, dementia and death.¹⁹ Ten years later, the first report on a validated VACS index specific for those with HIV infection was published.⁵ The VACS Index has, since then, been used to predict mortality in infected and uninfected populations and has been associated with the FFI.⁶ In the WIHS, the VACS Index and CES-D score considered together have been independently reported to predict mortality over a 5 year period.⁴ Here we show that with addition of the FFI, these relationships change.

The FFI predicts death, particularly among elderly (65 years and older).¹⁰ More recently the FFI has been measured in younger adult populations who may be at risk for premature or earlier aging, such as those with HIV infection.^{6,20} These studies have shown that adults with HIV infection, even in mid-life, experience a prevalence of frailty equivalent to, and greater than, that

1
2
3 observed in more elderly adults.^{4,9} The reason for this early manifestation of the frailty
4
5 phenotype may be a consequence of HIV infection itself, including suboptimal medication and
6
7 control of infection early on, comorbid diseases (infectious or non-infectious)^{4,21} and/or other
8
9 lifestyle habits that may be common among those with HIV infection, such as smoking and
10
11 substance use.¹¹ While interesting, FFI fluctuations cannot be addressed in these analyses, but
12
13 will be in the future with the re-initiation of FFI assessments in the WIHS in Fall 2015. As the
14
15 FFI is a marker of the slower process of physical aging, it may continue to be more strongly
16
17 associated with non-AIDS and later deaths as was seen in this analysis.
18
19
20
21
22
23

24
25 The CES-D was significantly associated with death in models that did not adjust for VACS and
26
27 FFI (HR=2.07, 95% CI 1.55, 2.7, $p<0.0001$, $\chi^2=24.0$ in Table 2), however it was not associated
28
29 with death once VACS and FFI indices were included in the same model. Several studies that do
30
31 not consider FFI and/or VACS, including those from the WIHS, have found CES-D to be a
32
33 significant “independent” predictor of mortality.^{4,15,22-25} This study calls into question whether
34
35 CES-D is a surrogate for other vulnerabilities rather than being independently and causally
36
37 associated with death. Other studies or analyses of CES-D in relation to death tend to not include
38
39 other health indices in their models or only include VACS.⁴ It should be noted that modifying the
40
41 CES-D to exclude two items potentially overlapping with the FFI (low physical activity and
42
43 exhaustion) did not change the failure of CES-D to be significant in the multivariate models
44
45 (data not shown). Evaluating vulnerabilities in middle-aged HIV-infected women (the average
46
47 age of infected women today) is important to understanding the impact of HIV infection on
48
49 mortality over the life course. This approach has been shown for other diseases of later-life.²⁶
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Midlife physical, biological and/or mental indicators against the background of HIV infection
4
5 may be associated with earlier death.
6
7

8
9
10 Why are multi-dimensional health indices associated with mortality in adults with HIV
11
12 infection? Throughout adult life, HIV infection is synergistic with adverse aging influences on
13
14 the immune, vascular, reproductive, and central nervous systems, thereby intensifying the aging
15
16 process.^{27,28} In our previous cross-sectional analysis of the FFI, we showed that the FFI is
17
18 associated with infectious, demographic, chronic disease, and biological factors, including
19
20 individual components of the VACS Index,⁴ lending support to this observation.
21
22
23
24

25
26
27 We chose to assess deaths occurring within 3 years versus those occurring ≥ 3 years after the
28
29 indices were measured. Studies in uninfected populations have shown that deaths occurring
30
31 within a short period of time (e.g., 3 years) tend to be those due to more rapid biological triggers
32
33 of death such as infections (e.g., HIV, pneumonia) or other acute illnesses, while longer term
34
35 deaths reflect delayed consequences of deteriorating biological and physical health.²⁹ Non-AIDS
36
37 deaths were predicted by FFI, whether those deaths occurred within versus later than 3 years.
38
39 VACS was more significant for AIDS deaths and deaths occurring within 3 years. Notably, both
40
41 VACS and FFI were stronger predictors of death (all, AIDS, non-AIDS) than age and other
42
43 variables considered in the multivariable models reflecting that these indices, more than age,
44
45 carried the consequences of deteriorating biological and physical health.
46
47
48
49
50

51
52
53 Some limitations of our approach may be that the VACS Index was specifically designed and
54
55 statistically weighted to predict mortality in HIV infected persons, and that the FFI was designed
56
57
58
59
60

1
2
3 to be descriptive of a clinically recognizable phenotype. Therefore the VACS Index may be
4
5 expected to have more explanatory power in multivariate analyses of survival. Furthermore,
6
7 there exist other frailty measures than FFI that also predict mortality.^{30,31} However, the VACS,
8
9 FFI and CES-D health indices were selected because they are typically reported in the literature
10
11 as being predictive of death in HIV+ samples. The point of our analyses was not to identify the
12
13 best mortality index *de novo*, but rather to systematically compare the three health indices that
14
15 have been reported in the literature. An additional limitation of these health indices, particularly
16
17 the FFI, is the blatant lack of standardization across studies. Our goal in these analyses, as
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Aging with HIV infection is associated with geriatric morbidities or syndromes, including frailty and other health indices denoting vulnerability,³² however these aging morbidities often occur earlier among those with HIV infection compared to uninfected individuals.³³⁻³⁶ The question is whether HIV infection leads to more severe aging phenotypes, or accelerates their onset leading to earlier age of death.³⁷ These analyses show that two health indices, the VACS (biological) index and the FFI (physical), independently predict mortality in middle-aged women with HIV infection; in particular VACS predicted AIDS death while FFI predicted non-AIDS death. Inclusion of CES-D, a depressive symptom scale, was not independently informative once both

1
2
3 the biological and physical health indices were considered. This is the first published report on
4
5 the simultaneous evaluation of these important indices in association with mortality in women
6
7 with HIV infection. These analyses point to the importance of designing interventions to address
8
9 components of multifaceted indices in the hopes of extending the lifespan of patients living with
10
11 chronic HIV.
12
13

14 15 16 17 18 **Author Contributions**

19 All authors contributed to this work. Hypothesis generation and manuscript drafting was led by
20
21 DRG, DRH, and RH; statistical analyses and interpretation were led by DRH and QS; data base
22
23 management was led by SG; participant recruitment and retention and collection of site-specific
24
25 health indices, covariates and outcomes data, were actively accomplished by the WIHS Principal
26
27 Investigators, DRG, HM, MHC, MWP, AS, MG, and JM and project staff, SH. Attainment of
28
29 funding and manuscript editing was performed by all.
30
31
32
33
34
35

36 37 **Funding Statement**

38 Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS)
39
40 Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx
41
42 Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff, Deborah Gustafson);
43
44 Washington DC, Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium
45
46 of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium
47
48 (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen
49
50 Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (U01-
51
52 AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-
53
54
55
56
57
58
59
60

1
2
3 42590) and by the *Eunice Kennedy Shriver* National Institute of Child Health and Human
4
5
6 Development (UO1-HD-32632). The study is co- funded by the National Cancer Institute, the
7
8 National Institute on Drug Abuse, and the National Institute on Deafness and Other
9
10 Communication Disorders. Funding is also provided by the National Center for Research
11
12 Resources (UCSF-CTSI Grant Number UL1 RR024131). Data collection was supported by a
13
14 dissertation grant through the National Institute of Drug Abuse (1R36DA021104-01). In
15
16 addition, Dr. Gustafson received support from NIH/NIAID ARRA Supplement No. 54492,
17
18 Swedish Research Council for Health, Working Life and Welfare (AGECAP 2013-2300) and the
19
20 State University of New York Research Foundation.
21
22
23
24
25
26

27 The contents of this publication are solely the responsibility of the authors and do not necessarily
28
29 represent the official views of the National Institutes of Health.
30
31
32
33

34 We thank the women participating in WIHS for their time, cooperation, and support.
35
36
37
38

39 **Competing Interest**

40 There are no competing interests to declare.
41
42
43
44

45 **STROBE Criteria**

46 This manuscript meets the STROBE criteria for longitudinal cohort studies.
47
48
49
50
51

52 **Data Sharing**

53
54 Technical appendix, statistical code, and dataset are available from the WIHS Statistical Analysis
55
56 Center, WD-MAC.
57
58
59
60

REFERENCES

1. Kirk JB, Goetz MB. Human immunodeficiency virus in an aging population, a complication of success. *Journal of the American Geriatrics Society* 2009; **57**(11): 2129-38.
2. Vance DE, McGuinness T, Musgrove K, Orel NA, Fazeli PL. Successful aging and the epidemiology of HIV. *Clin Interv Aging* 2011; **6**: 181-92.
3. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. *PloS one* 2013; **8**(12): e81355.
4. Cohen MH, Hotton AL, Hershov RC, et al. Gender-related risk factors improve mortality predictive ability of VACS Index among HIV-infected women. *J Acquir Immune Defic Syndr* 2015.
5. Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. *J Acquir Immune Defic Syndr* 2013; **62**(2): 149-63.
6. Escota GV, Patel P, Brooks JT, et al. Short communication: The Veterans Aging Cohort Study Index is an effective tool to assess baseline frailty status in a contemporary cohort of HIV-infected persons. *AIDS research and human retroviruses* 2015; **31**(3): 313-7.
7. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *The journals of gerontology Series A, Biological sciences and medical sciences* 2001; **56**(3): M146-56.
8. Rizzoli R, Reginster JY, Arnal JF, et al. Quality of life in sarcopenia and frailty. *Calcif Tissue Int* 2013; **93**(2): 101-20.
9. Terzian AS, Holman S, Nathwani N, et al. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. *J Womens Health (Larchmt)* 2009; **18**(12): 1965-74.
10. Shamliyan T, Talley KM, Ramakrishnan R, Kane RL. Association of frailty with survival: a systematic literature review. *Ageing Res Rev* 2013; **12**(2): 719-36.
11. Piggott DA, Muzaale AD, Mehta SH, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. *PloS one* 2013; **8**(1): e54910.
12. Ravindrarajah R, Lee DM, Pye SR, et al. The ability of three different models of frailty to predict all-cause mortality: Results from the European Male Aging Study (EMAS). *Archives of gerontology and geriatrics* 2013; **57**(3): 360-8.
13. Andrew MK, Fisk JD, Rockwood K. Psychological well-being in relation to frailty: a frailty identity crisis? *International psychogeriatrics / IPA* 2012; **24**(8): 1347-53.
14. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. *Clin Diagn Lab Immunol* 2005; **12**(9): 1013-9.
15. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. *The American journal of medicine* 2002; **113**(2): 91-8.
16. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; **150**(9): 604-12.
17. Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. *Psychol Aging* 1997; **12**(2): 277-87.
18. Newson RB. Comparing the predictive powers of survival models using Harrell's C or Somers' D. *Stata Journal* 2010; **10**: 339-58.

19. Hirsch C, Anderson ML, Newman A, et al. The association of race with frailty: the cardiovascular health study. *Annals of epidemiology* 2006; **16**(7): 545-53.
20. Erlandson KM, Schrack JA, Jankowski CM, Brown TT, Campbell TB. Functional impairment, disability, and frailty in adults aging with HIV-infection. *Curr HIV/AIDS Rep* 2014; **11**(3): 279-90.
21. Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. *Infection* 2004; **32**(1): 33-46.
22. Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. *Am J Public Health* 2004; **94**(7): 1133-40.
23. Coughlin SS. Invited commentary: Prevailing over acquired immune deficiency syndrome and depressive symptoms. *American journal of epidemiology* 2013; **177**(2): 126-8; discussion 9-30.
24. Farinpour R, Miller EN, Satz P, et al. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). *J Clin Exp Neuropsychol* 2003; **25**(5): 654-70.
25. Lyketsos CG, Hoover DR, Guccione M, et al. Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study. *JAMA* 1993; **270**(21): 2563-7.
26. Ritchie K, Ritchie CW, Yaffe K, Skoog I, Scarmeas N. Is late-onset Alzheimer's disease really a disease of midlife? *Translational Res Clin Interventions* 2015; **1**: 122-30.
27. Nguyen N, Holodniy M. HIV infection in the elderly. *Clin Interv Aging* 2008; **3**(3): 453-72.
28. Kalayjian RC, Landay A, Pollard RB, et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. *J Infect Dis* 2003; **187**(12): 1924-33.
29. Gustafson DR, Mazzucco S, Ongaro F, et al. Body mass index, cognition, disability, APOE genotype, and mortality: the "Treviso Longeva" Study. *Am J Geriatr Psychiatry* 2012; **20**(7): 594-602.
30. Kulminski AM, Ukraintseva SV, Kulminskaya IV, Arbeev KG, Land K, Yashin AI. Cumulative deficits better characterize susceptibility to death in elderly people than phenotypic frailty: lessons from the Cardiovascular Health Study. *Journal of the American Geriatrics Society* 2008; **56**(5): 898-903.
31. Theou O, Brothers TD, Mitnitski A, Rockwood K. Operationalization of frailty using eight commonly used scales and comparison of their ability to predict all-cause mortality. *Journal of the American Geriatrics Society* 2013; **61**(9): 1537-51.
32. Greene M, Covinsky KE, Valcour V, et al. Geriatric syndromes in older HIV-infected adults. *J Acquir Immune Defic Syndr* 2015; **69**(2): 161-7.
33. Gustafson DR, Shi Q, Thurn M, et al. Frailty and constellations of factors in aging HIV-infected and uninfected women--The Women's Interagency HIV Study. *J Frailty Aging* 2016; **5**(1): 43-8.
34. Desquilbet L, Jacobson LP, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. *The journals of gerontology Series A, Biological sciences and medical sciences* 2007; **62**(11): 1279-86.

- 1
2
3 35. Desquilbet L, Jacobson LP, Fried LP, et al. A frailty-related phenotype before HAART
4 initiation as an independent risk factor for AIDS or death after HAART among HIV-infected
5 men. *The journals of gerontology Series A, Biological sciences and medical sciences* 2011;
6 **66**(9): 1030-8.
7
8 36. Desquilbet L, Margolick JB, Fried LP, et al. Relationship between a frailty-related
9 phenotype and progressive deterioration of the immune system in HIV-infected men. *J Acquir*
10 *Immune Defic Syndr* 2009; **50**(3): 299-306.
11 37. Onen NF, Overton ET. A review of premature frailty in HIV-infected persons; another
12 manifestation of HIV-related accelerated aging. *Current aging science* 2011; **4**(1): 33-41.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Figure 1. WHS participants with the VACS Index, FFQ, and CES-D measured in 2005**
4 **and follow-up over approximately 8 years.**
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Baseline characteristics of HIV+ WIHS participants who are not ART-naïve

Variables	N (%) or Mean ± SD
Indices	
Fried Frailty Index (FFI)	
0-2 points	1143 (82.5)
3-5 points	242 (17.5)
VACS Index Score (0-164 points)	28.9 ±19.4
CES-D score ≥ 16 points	
No	844 (60.9)
Yes	541 (39.1)
Outcomes	
All Deaths	
3 Years or Less	73 (5.3)
> 3-8 years	111 (8.0)
AIDS deaths ^a	
3 Years or Less	39 (2.8)
> 3-8 years	35 (2.5)
Non-AIDS deaths ^a	
3 Years or Less	32 (2.3)
> 3-8 years	45 (3.2)
HIV variables	
CD4 count (cells/mm ³)	
≥ 500	554 (40.0)
200-499	614 (44.3)
< 200	217 (15.7)
Viral Load (copies/ml)	
< 500	820 (59.2)
500-100,000	510 (36.8)
>100,000	55 (4.0)
Hemoglobin (g/dl)	
≥ 14	209 (15.1)
12-13.9	743 (53.6)
10-11.9	362 (26.1)
<10	71 (5.1)
FIB4	
< 1.45	1018 (73.5)
1.45-3.25	280 (20.2)
> 3.25	87 (6.3)
eGFR (ml/min)	
≥ 60	1277 (92.2)
45-59.9	71 (5.1)
30-44.9	15 (1.1)
< 30	22 (1.6)
Hepatitis C Co-infection	298 (21.5)

Demographic Variables

Average age (years, mean \pm SD)	42.6 \pm 8.8
Race/Ethnicity	
White	324 (23.4)
Black	806 (58.2)
Others	255 (18.4)
Education	
< High School	536 (38.7)
\geq High School	847 (61.2)
Missing	2 (0.1)
Smoking History	
Not current smoking	786 (56.8)
Current smoking	599 (43.2)
Income	
< \$12,000	669 (48.3)
\geq \$12,000	668 (48.2)
Missing	48 (3.5)
Current Alcohol Drinking	
Abstainer/None	743 (53.6)
Low	490 (35.4)
Moderate	129 (9.3)
High	23 (1.7)
Body Mass Index (BMI), kg/m ²	
BMI < 30	916 (66.1)
BMI \geq 30 (Obesity)	461 (33.3)
Missing	8 (0.6)
Current ART use	
No	400 (28.9)
Yes (HAART)	984 (71.0)
Missing	1 (0.1)
Prior AIDS Defining Illness	
No	802 (57.9)
Yes	583 (42.1)
Injection Drug Use Ever	
Yes	305 (22.0)
No	1071 (77.3)
Missing	9 (0.6)
Prior Pneumonia	
No	1080 (78.0)
Yes	305 (22.0)
Current / Prior Hypertension	
No	964 (69.6)
Yes	421 (30.4)
History of Diabetes	

No	1195 (86.3)
Yes	190 (13.7)
Prior Cancer Diagnosis	
No	1220 (88.1)
Yes	165 (11.9)

^aFor some deaths, cause of death could not be classified as AIDS / non-AIDS, thus the numbers of AIDS + non-AIDS deaths do not sum to total deaths

For peer review only

Table 2. Proportional Hazards models of time to all deaths by FFI, VACS Index, CES-D, age group, and potential confounders among HIV+ women who are not ART naïve.

Variable	Crude HR (95% CI)	χ^2	P-value
Univariate Analyses of Indices			
VACS Score (0-164), per 20 points	2.20 (1.98, 2.45)	214.6	< 0.0001
FFI 3-5 vs 0-2	3.92 (2.92, 5.26)	83.2	< 0.0001
CES-D (< 16 vs \geq 16)	2.07 (1.55, 2.77)	24.0	<0.0001
Univariate Analyses of Potential Confounders			
Age per Decade	1.62 (1.38, 1.89)	36.14	<0.0001
Race/ethnicity		8.95 (2 df)	0.011
White vs black	0.55 (0.37, 0.83)	8.02	0.005
Others vs black	0.74 (0.49, 1.11)	2.15	0.140
Education \geq high school vs < high school	0.68 (0.51, 0.90)	6.96	0.008
Smoking (current vs no)	3.41 (2.49, 4.69)	57.5	<0.0001
Income (< \$12,000 vs \geq \$12,000)	2.03 (1.49, 2.77)	19.8	<0.0001
Drinking		27.25 (3 df)	<0.0001
Low vs Abstainer/None	0.59 (0.42, 0.84)	8.59	0.003
Moderate vs Abstainer/None	1.27 (0.82, 1.98)	1.14	0.290
High vs Abstainer/None	3.48 (1.76, 6.87)	12.9	0.0003
BMI, kg/m ² (\geq 30 vs <30)	0.57 (0.41, 0.81)	10.2	0.001

Table 3. Concordance statistics from Proportional hazards models for health indices used to predict death among HIV+ women who were not ART naïve.

Variables	All deaths	AIDS deaths	Non-AIDS deaths
CES-D + VACS Index + FFI	0.83	0.89	0.81
+ Demographics ^a			
VACS Index + FFI +	0.83	0.89	0.81
Demographics			
VACS Index + CES- D +	0.82	0.89	0.78
Demographics			
FFI + CES-D +	0.78	0.80	0.80
Demographics			
VACS Index +	0.81	0.89	0.77
Demographics			
FFI + Demographics	0.77	0.78	0.80
CES-D + Demographics	0.75	0.77	0.75
Demographics Only*	0.74	0.74	0.76

^aDemographic variables included were: age, BMI, race/ethnicity, income, education, cigarette smoking & alcohol use.

Table 4. VACS Index, FFI, and CES-D individually predict time to all, AIDS and non-AIDS deaths over ~8 years follow-up among HIV+ women who are not ART naïve.

Index	All deaths			AIDS deaths			Non-AIDS deaths		
	χ^2	HR ^a (95% CI)	P-value	χ^2	HR (95% CI)	P-value	χ^2	HR (95% CI)	P-value
VACS Score (0-164), per 20 points	89.81	1.82 (1.61, 2.06)	<0.0001	94.95	2.52 (2.09, 3.04)	>0.0001	21.22	3.27 (1.97, 5.40)	<0.0001
FFI 3-5 vs 0-2	24.70	2.35 (1.68, 3.28)	<0.0001	8.44	2.27 (1.30, 3.93)	0.004	6.13	1.31 (1.06, 1.62)	0.013
CES-D (< 16 vs \geq 16)	0.75	1.16 (0.83, 1.60)	0.38	2.04	1.49 (0.86, 2.59)	0.15	0.17	0.90 (0.55, 1.48)	0.68
Age per decade	2.03	1.15 (0.95, 1.39)	0.15	2.88	0.77 (0.56, 1.04)	0.09	7.48	1.50 (1.12, 2.01)	0.006

^aMultivariate models included race/ethnicity; education less than or equal to vs greater than high school; smoking current vs no; income less than vs greater than or equal to \$12,000 annually; alcohol use: low, moderate or high vs none; and BMI at least than vs less 30 kg/m²

Table 5. Multivariable proportional hazards models of time to all, AIDS and non-AIDS deaths within 3 years vs greater than 3 years by VACS Index, FFI, CES-D and age among HIV+ women who are not ART naïve.

Variable	A. All Deaths Within 3 Years After FFI Visit			B. All Deaths Later Than 3 Years After FFI Visit		
	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-value	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-Value
VACS Index per 20 points	69.04	2.20 (1.83, 2.65)	<0.0001	23.88	1.55 (1.30, 1.84)	<0.0001
FFI (3-5 vs 0-2 points)	6.73	2.06 (1.19, 3.57)	0.01	16.18	2.43 (1.58, 3.75)	0.0001
CES-D (< 16 vs \geq 16 points)	1.01	1.32 (0.77, 2.28)	0.31	0.11	1.07 (0.71, 1.62)	0.74
Age per Decade	0.09	1.05 (0.77, 1.42)	0.76	3.24	1.26 (0.98, 1.61)	0.07
Variable	C. AIDS Deaths Within 3 Years or Less After FFI Visit			D. AIDS Deaths Later Than 3 Years After FFI Visit		
	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-value	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-Value
VACS Index per 20 points	80.32	3.33 (2.56, 4.33)	0.0000	13.97	1.75 (1.31, 2.35)	0.0002
FFI (3-5 vs 0-2 points)	0.88	1.45 (0.67, 3.14)	0.34	9.40	3.38 (1.55, 7.37)	0.002
CES-D (< 16 vs \geq 16 points)	1.96	1.73 (0.80, 3.73)	0.17	0.81	1.43 (0.65, 3.14)	0.37
Age per Decade	2.42	0.72 (0.47, 1.09)	0.12	0.09	0.93 (0.58, 1.50)	0.77

	E. Non-AIDS Deaths Within 3 Years or Less After FFI Visit			F. Non-AIDS Deaths Later Than 3 Years After FFI Visit		
	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-value	χ^2	Multivariate-Adjusted HR ^a (95% CI)	P-Value
VACS Index per 20 points	0.80	1.16 (0.83, 1.62)	0.37	5.84	1.41 (1.07, 1.86)	0.016
FFI (3-5 vs 0-2 points)	9.15	3.37 (1.53, 7.40)	0.003	11.95	3.20 (1.66, 6.20)	0.0005
CES-D (< 16 vs ≥16 points)	0.15	1.17 (0.54, 2.54)	0.70	0.60	0.77 (0.40, 1.48)	0.44
Age per Decade	7.43	1.90 (1.20, 3.02)	0.006	1.44	1.26 (0.86, 1.84)	0.23

^aMultivariate models included race/ethnicity; education less than or equal to vs greater than high school; smoking current vs no; income less than vs greater than or equal to \$12,000 annually; alcohol use: low, moderate or high vs none; and BMI at least than vs less 30 kg/m²




Figure 1. WIHS participants with the VACS Index, FFI, and CES-D measured in 2005 and follow-up over approximately 8 years.

245x183mm (96 x 96 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies
All items in the STROBE checklist are accomplished, see page numbers by items listed below.

	Item No & Page#	Recommendation
Title and abstract	1, P1	(a) Indicate the study's design with a commonly used term in the title or the abstract
	P3	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2, P5-6	Explain the scientific background and rationale for the investigation being reported
Objectives	3, P6	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4, P6	Present key elements of study design early in the paper
Setting	5, P6-9	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6, P6-7	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7, P7-9	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*, P7-9	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias, NA
Study size	10, P7	Explain how the study size was arrived at
Quantitative variables	11, P9-10	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12, P9-10	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
	P9-10	(c) Explain how missing data were addressed, NA
		(d) <i>Cohort study</i> —If applicable, explain loss to follow-up was addressed, NA <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed, NA <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy, NA
		P10

Continued on next page

Results		
Participants	13*,	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
	P31	(b) Give reasons for non-participation at each stage, NA
	P31	(c) Consider use of a flow diagram
Descriptive data	14*,	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
	P23-25	(b) Indicate number of participants with missing data for each variable of interest, NA
	P31	(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*, P7-	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time
	9, P31	<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure, NA
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures, NA
Main results	16, P10-	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
	13	(b) Report category boundaries when continuous variables were categorized
	P8-9	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period, NA
Other analyses	17, P11	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18, P12-13	Summarise key results with reference to study objectives
Limitations	19, P15-16	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20, P12-17	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21, P4, P12-17	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22, P17-18	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.